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Abstract
Many children under the age of 5 die each year of invasive pneumococcal disease.
Childhood vaccination against this disease reduces morbidity and mortality. Despite the
introduction of a pneumococcal conjugate vaccine (PCV13) in a central African country
in 2011, all provinces have not yet been vaccinated. The purpose of this quantitative
quasi-experimental study was to determine whether there was an association between the
introduction of PCV13 and new cases of pneumococcal disease in 2 provinces in central
Africa. The sample size for the study was 380. The theoretical framework for this study
was the epidemic model supported by the concept of herd immunity. Key research
questions examined the incidence of pneumococcal disease in children by age, gender,
and province. The independent variables were age, gender, province, and introduction of
PCV13. The dependent variable was incidence of invasive pneumococcal disease. The
research questions were evaluated using chi-square test of independence and logistic
regression. The results of the study indicated that vaccination with PCV13 significantly
reduced incident cases of invasive pneumococcal diseases (aOR 0.333, 95% CI 0.6280.177, p = 0.001). However, this association was not significant for age (aOR 0.574, 95%
CI 1.186-0.278, p = .134), and there were no significant gender differences (aOR 1.047,
95% CI 1.929-0.569, p = 0.882). Positive social change may result by enabling the
protection of more children in the central Africa country provinces that have not yet
adopted using PCV13 and by introducing the vaccine in other African countries.
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Chapter 1: Introduction to the Study
Introduction
The gram-positive bacterium that causes invasive pneumococcal infections (such
as pneumonia, septicemia, and meningitis) especially in children is the streptococcus
pneumoniae (S. Pneum) or streptococcus; this bacterium is a normal inhabitant of the
upper respiratory track flora (Grall et al., 2011). According to the Centers for Disease
Control and Prevention (CDC, 2011), in 2008, about 1.6 million children less than 5
years of age die because of pneumococcal diseases worldwide each year, and over 95 %
of them of these deaths occur in the developing world. This shows that the disease is a
public health concern for younger children with a higher burden for the under developed
world.
Pneumococcal infection starts with the bacteria colonizing in the nasopharynx of
healthy children, where it grows and establishes a carriage. At this stage, the
pneumococcus can either remain asymptomatic or can take three different paths:
potentially causing otitis media (ear ache) by migrating through the eustachian tube,
pneumonia by descending down the respiratory tract, or meningitis by invading the
bloodstream through the respiratory epithelium (Dube, Kaba, Whittaker, Zar, & Nicol,
2013). Forty six serogroups and at least 93 serotypes of streptococcus pneumoniae have
been identified (Coskun-Ari1, Guldemir, & Durmaz, 2012). So far, only a small number
of the 93 serotypes have been detected from patients with invasive pneumococcal disease
worldwide; that number was distributed according to age, sex, and geography (Dashti,
Abdinia, & Karimi, 2012). Pneumococcal infection is treated with antibiotics, but more
pneumococci are becoming resistant to antibiotics; therefore, attention needs to be placed

2
on the prevention of the disease in order to reduce morbidity and mortality (Liňares,
Ardanuy, Pallares, & Fenol, 2010).
The most cost effective prevention of pneumococcal disease in children is through
vaccination with pneumococcal conjugate vaccine (PCV) (Pittet, & Posfay-Barbe, 2012).
The protection is achieved by the induction of a protective antibody response against the
bacterial polysaccharide capsule. PCV vaccine available to date only includes antibodies
against 13 out of the 93 serotypes (Weil-Olivier, van der Linden, de Schutter, Dagan, and
Mantovani, 2012). Three different vaccines have been developed; starting with the seven
valents (PCV7) containing the seven most diseases causing serotypes that are 4, 6B, 9V,
14, 18C, 19F, and 23F; followed by the 10 valents (PCV10) containing three additional
serotypes (1, 5, 7F), and the PCV 13 containing six additional serotypes 1, 3, 5, 6A, 7F,
and 19A (Weil-Olivier et al., 2012). Even though PCV 7 has reduced the incidence of the
disease, pneumococcal disease was caused by the non vaccine serotype in some cases
(Weil-Olivier et al., 2012); therefore, a vaccine covering more serotypes was needed,
resulting in the development of PCV10 and PCV13.
According to the Democratic Republic of Congo (DRC’s) Ministry of health,
beginning in April 2011, the vaccine began to be introduced in DRC by province to
eventually cover the entire country. Therefore, it is important to study the impact of the
vaccine in the reduction of the burden of the disease in order to cover the entire country
in DRC and/or other African countries. The PCV13 shields 13 serotypes, which is highly
effective; however, more research is needed for the development of vaccines with greater
coverage in the future. To achieve this, it will be crucial to monitor the circulating
serotypes in a given geographical area to evaluate the effectiveness of the vaccine
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available in that setting, and then compare the circulating strains and the ones included in
the vaccine (Sakai, Talekar, Klugman, & Vidal, 2013). An effective vaccine has the
potential to eliminate many sick children and unnecessary deaths due to pneumococcal
infections.
The chapter begins with the background of the problem, problem statement, and
significance of the study. The chapter includes the research questions that guided the
study, as well as a short definition of main terms. The theoretical framework for the study
is also presented, with further discussion provided in the literature review. In these
sections, I establish the goals for the study and illustrate the need for continued
pneumococcal vaccine research in the field of health.
Background of the Study
Pneumococcal disease is caused by infection with streptococcus pneumoniae
bacteria. These bacteria can spread from one person to another person through close
contact (CDC, 2013). Pneumococcal disease can lead to severe health problems,
including pneumonia, blood infections, and meningitis (CDC, 2013). Pneumococcal
infection is generally preceded by a colonization of germs in the nasopharynx, which is
usually asymptomatic (without symptoms) in most of the cases and does not turn into the
disease (Dube et al., 2013). When the colonization transitions to the disease phase, it can
be severe, affecting a child’s quality of life, and sometimes death occurs (Rodewald,
Maes, Stevenson, Lyons, Stokley, & Szilagyi, 1999). The asymptomatic carrier state is
mostly seen in children attending daycare centers; therefore, those children constitute the
reservoir (disease carrier) for the pneumococci bacteria (Rodewald et al., 1999).
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Pneumococcal disease is prevented with available pneumococcal vaccines. As of
2012, the World Health Organization recommended using pneumococcal vaccines as a
part of the routine childhood vaccination schedule; 86 countries have introduced the
vaccine including 23 low-income member states. The 23 low-income countries had the
assistance of the Global Alliance for Vaccines and Immunizations (GAVI) to finance the
vaccine (WHO, 2012). The burden of pneumococcal disease caused by streptococcus
pneumoniae in sub-Saharan Africa has prompted the GAVI Alliance to finance the
introduction of the vaccine in several countries including the DRC (WHO, 2012).
According to the WHO (2013), pneumonia was the leading cause of death in the DRC
since the year 2000 as compared to all other causes of death in children less than 5 years
of age. Research has been conducted to study the impact of the pneumococcal conjugate
vaccine on the reduction of invasive pneumococcal diseases in different countries, but no
studies have been conducted in the DRC. In this study, I address the gap in knowledge of
the impact of the PCV13 on the circulating strains of streptococcus pneumoniae in the
DRC.
Low-income countries face difficulty in affording and sustaining quality
lifesaving vaccines; therefore, in order for their programs to generate the most desirable
outcomes from a public health standpoint, alternative solutions need to be put in place.
Due to the high cost of vaccines and the difficulties in sustainability, manufacturing
appropriate vaccine products has proven to be difficult due to underinvestment. Peltola,
Booy, and Schmitt (2004) claimed that the high cost of vaccines keeps many children
from getting a highly effective vaccine against the pneumococcal diseases. There is a
need to make the vaccine more accessible to the children most at risk. To remove some of
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the market risks, a pilot initiative called the Advance Market Commitment (AMC) for
pneumococcal vaccines was launched in 2009 (Cernuschi et al., 2011). These initiatives
set predetermined terms that legally bind the purchasing of vaccines. To date, 14
countries have already introduced pneumococcal vaccines through the AMC with 39
countries expected to introduce before the end of 2013 (Cernuschi et al., 2011). This has
helped protect more children through routine vaccination therefore reduce the burden of
the disease.
Problem Statement
There is a high incidence of pneumococcal diseases among children worldwide.
Pneumococcal disease is classified as the leading cause of mortality and morbidity in
children worldwide (Cohen, Hyde, Verania, & Watkins, 2012). Prevention of the disease
is important in reducing the morbidity and mortality of the disease and the best, most
cost-effective prevention is immunization through childhood vaccination (CDC, 2012).
Antao and Hausdorff, (2009) claimed that there is a high burden of pneumococcal
diseases in children and stated that the disease can be prevented with an available
vaccine. The bulk of pneumococcal research has focused on the burden and antibiotic
treatment, without giving equal attention to the prevention of the disease with the
available vaccines and the effectiveness of the vaccine. This discrepancy led scholars to
examine the pneumococcal conjugate vaccine, which may help reduce the morbidity and
mortality of the invasive form of the disease.
Although the vaccine has been shown to have an impact in some African
countries as well as some South and North American and Europeans countries, there was
a need to determine the effects of the vaccine on the circulating serotypes in the DRC.
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Starting in April 2011, according to the DRC’s Ministry of health, the pneumococcal
conjugate vaccine (PCV13) began gradually being introduced into the DRC’s expanded
program of immunization to eventually cover the whole country; thus far, it has reached
five of the country’s 11 provinces: The first two provinces (Kinshasa and Bas Congo)
introduced the vaccine in April 2011, followed by two other provinces (Nord Kivu and
South Kivu) in July 2011 and the province of Bandundu in October 2011. A total of
677,308 children were targeted in the five provinces, and as of July 2013 the coverage
with PCV13 was 88.8% as reported by the DRC’s immunization authority. Evaluation of
the effectiveness of the vaccine was a key step in continuing with the introduction of the
vaccine to the entire country; therefore, there was a need to evaluate the provinces that
have immunized thus far.
Purpose of the Study
The purpose of this quantitative secondary data analysis was to determine if a
relationship existed between two DRC provinces where PCV13 had been introduced/not
introduced and determine if the covariates (age and gender) had an impact on that
relationship. The intent of this study was to examine the relationship between DRC
provinces’ childhood immunization rates for pneumococcal vaccine and the incidence of
invasive pneumococcal disease. The independent variable was province (Kinshasa,
Katanga). The dependent variable was the number of incident cases (observed, not
observed).
An association between the pneumococcal vaccination rates of children who have
routinely been vaccinated against the disease and the prevention of the disease might
create a reason for other DRC cities and provinces to mandate the routine use of the
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vaccine for all young children. Health care personnel in the DRC might be more
motivated to routinely recommend and use the vaccine if they understand through
evidentiary data that children’s lives will be improved by eliminating this disease from
their lives.
Research Questions and Hypotheses
RQ1: What is the difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV13 and a comparison group in the Katanga province where the
vaccine was not introduced?
Directional Hypothesis 1:
H01: There is no difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV 13 and the Katanga province where the vaccine was not introduced.
Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a
decrease in the number of incident cases of invasive pneumococcal disease as compared
to the children of the same age in the Katanga province where the vaccine was not
introduced.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: province type: (Kinshasa, Katanga)



Statistical analysis: Chi-square test of independence

RQ2: Is there an association between age and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
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Directional Hypothesis 2:
H02: There is no association between age and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha2: Older children (2-5 years) were more likely to contract invasive
pneumococcal disease in the control province compared to the PCV13 intervention
province


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Age



Statistical analysis: Logistic regression

RQ3: Is there an association between gender and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
Directional Hypothesis 3:
H03: There is no association between gender and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha3: Males were more likely to contract invasive pneumococcal disease in the
control province compared to the PCV13 intervention province.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Gender



Statistical analysis: Logistic regression
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The objective of this study was to determine whether vaccinating young children
against pneumococcal disease protected one community better than those communities
that have not yet adopted routine vaccination with pneumococcal vaccine. The
pneumococcal vaccination of young children has been shown to prevent serious illness,
hospitalizations, and even death (Rodewald et al., 1999). If vaccination of young children
against pneumococcal disease had an additional benefit to protect communities, then
there may be an additional reason to require health care personnel to use the available
PCV vaccines.
Theoretical Framework
The theoretical framework for this study was the epidemic model, supported by
the concept of herd immunity. An epidemic model is based on the following assumptions:
(a) infectious disease is transmitted by person-to-person contact only; (b) persons
susceptible to the disease will develop the disease after contact with an infected person,
thereby acquiring immunity to the illness; (c) there is a fixed probability of coming in
contact with an infectious person; (d) the population has no contact with anyone outside
the community; and (e) the conditions remain constant throughout the epidemic (Fine,
1977). Herd immunity or threshold protects susceptible individuals in a community from
disease assuming there is a minimum vaccination threshold (Libster & Edwards, 2011, p.
163; Piedra et al., 2005). Herd immunity applies to infectious disease that can be
transmitted from person to person.
Nature of the Study
A quantitative, quasi-experimental research design was used to test the
hypotheses. I used this design because I wished to examine the effect of the vaccination
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and age and gender and looking prospectively at who got the disease and who did not. I
evaluated an intervention site with another site not receiving the intervention. The data
were collected during routine surveillance of the invasive pneumococcal diseases. A
quantitative approach was appropriate because the hypotheses derive from the theoretical
framework.
The study was guided by three research questions about whether or not there was
a difference in the number of incident cases of invasive pneumococcal disease between
the children in Kinshasa province following the introduction of PCV13 and a comparison
group in the Katanga province where the vaccine was not introduced. The dependent
variable for H1-H3 was number of incident cases of the disease. The independent
variables were province type (Kinshasa or Katanga), gender (male, female) and age
groups.
Archival data on the entire population that were extracted from the surveillance
system data were used. Archival data represented the best method because it was not only
less time consuming than collecting the data on my own, but they were readily available.
The data were originally collected as part of the normal surveillance system of the DRC
ministry of health (Frankfort-Nachmias & Nachmias, 2008). Permission was received
from the government of the DRC for use of the archival data in the study (Appendix B).
The data were originally collected after administration of a questionnaire (Appendix C) to
each visiting patient.
The population for this study was children who lived in the DRC, and who had
been immunized with PCV13 starting in April 2011 as recorded in an official regional
immunization record in the Kinshasa province; a comparison group of the same age
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group in the Katanga province was used where the vaccine was not introduced. The
sample was taken from the sentinels surveillance data of pneumococcal disease in the
municipalities of Kalembelembe, Kingasani of the Kinshasa province and the hospital of
Sendwe in the Katanga Province in DRC. There were an estimated 67.51 million people
in the DRC including 3 400 000 children in the year 2012 (WHO, 2013). According to
the DRC’s immunization authority, as of July 2013, 958 809 (54.4%) children less than
1-year-old received the first dose of PCV13 against 675977 (38.4%) who received the
third dose. In 2009 the pneumococcal disease incidence was ≥ 3000 per 100,000 children
less than 5 years of age; the mortality rate was between 300 and 500 per 100,000 children
less than 5 years of age (Wang, 2009). In the same year, DRC was among the 10
countries with the greatest pneumococcal deaths in the world all of which are in Africa
and Asia (Wang, 2009).
Definitions
The following definitions are commonly used in public health to describe
pneumococcal vaccination as it relates to health care:
Antibodies: Proteins generally found in the blood that detect and destroy invaders,
like bacteria and viruses. Part of the immune system, antibodies come in different types,
called isotypes. Mammals carry five isotypes. Each performs a different role in the body
(Jewett-Tennant, 2013).
Bacteria: Any of a large group of single-celled microorganisms that display a
wide range of metabolic types, geometric shapes, and environmental habitats and niches
of occurrence. Normally only several micrometers in length, bacteria assume the form of
spheres, rods, spirals, and other shapes (Vidyasagar, 2015).
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Eustachian tube: A passage from the tympanum of the ear to the pharynx
(Merriam Co, 1913).
Gram positive Bacteria: A bacterium that retains the violet stain used in Gram's
method. In gram positive bacteria, about 90% of the cell wall is made up of
peptidoglycan and small amounts of teichoic acid (Amils, 2011).
Herd immunity: Herd immunity is a public health prevention strategy to reduce
ongoing transmission of vaccine-preventable diseases (Plans-Rubió, 2012). When a
sufficient number of individuals are immune to a disease, the disease cannot continue to
be transmitted person-to-person (Plans-Rubió, 2012). Herd immunity works to reduce
risk of infection in the susceptible person by surrounding them with people who are
immune to the disease.
Infection: An invasion by and multiplication of pathogenic microorganisms in a
bodily part or tissue, which may produce subsequent tissue injury and progress to overt
disease through a variety of cellular or toxic mechanisms (Thomson & Smith, 1994).
Nasopharynx: The area of the upper throat that lies behind the nose (Moss, 1989)
Meningitis: According to CDC (2014), meningitis is defined as the inflammation
of the membranes of the brain or spinal cord.
Otitis media: An acute or chronic inflammation of the middle ear. An acute
inflammation, especially in infants or young children, that is caused by a virus or
bacterium; usually occurs as a complication of an upper respiratory infection; and is
marked by earache, fever, hearing loss, and sometimes rupture of the tympanic
membrane (Berman, 1995).
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Pneumonia: The inflammation of one or both lungs, with dense areas of lung
inflammation. It is a lower respiratory tract infection associated with typical
inflammation clinical sign such as fever, and problem breathing. (Gereige & Laufer,
2013)
Respiratory epithelium: The tissue lining the mouth, nose, throat, and trachea.
This lining acts as a barrier between the air coming into the body and the inner tissues of
the respiratory mechanism, and it also serves to warm, clean, and moisten the air in
preparation for its arrival in the lungs (McDowell, Barrett, Glavin, Harris, & Trump,
1978).
Septicemia: A term referring to the presence of pathogenic organisms in the
bloodstream, leading to sepsis (Stibich, 2014).
Serotype: A category into which material, usually a bacterium, is placed based on
its serological activity, in terms of the antigens it contains or the antibodies produced
against it (CDC, 2014).
Vaccine: A preparation of killed microorganisms, living attenuated organisms, or
a living fully virulent organism that is administered to produce or artificially increase
immunity to a particular disease. Vaccines are made of a microorganism that resembles
the disease causing one. (WHO, 2014).
Assumptions
The following assumptions were made about this study:
1.

The study sample was children who have visited one of the three sentinel
surveillance sites in the municipalities of Kalembelembe, Kingasani in
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Kinshasa; province of Kinshasa; and the hospital of Sendwe in the town of
Lubumbashi, Province of Katanga.
2.

It was assumed that children visiting the sentinel surveillance sites had not
biased the study, and that the archival data used were of a good quality.

3.

It was presumed that the instruments used were the appropriate means for
measuring the variables chosen.

4.

The generalizability of this study may have been good for similar
populations of provinces having introduced the vaccine and those having
not introduced.

5.

The study was enhanced by measuring the immunization status of the
study participants.

6.

The vaccination status with the number of doses may have reflected the
immunization responses.

7.

Objective immunization status measures may have helped identify those at
risk for pneumococcal invasive diseases after demonstrating the impact of
the vaccine.
Scope and Delimitations

The scope of the study was the pneumococcal vaccination of young children in
the province of Kinshasa in the DRC and whether or not children were better protected
from pneumococcal disease when compared to other DRC cities and provinces that have
not yet routinely adopted pneumococcal vaccine. The time period was 2009 to July 2013.
The delimitations of this study were the following:
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1.

The study was delimited to an archival, quantitative, correlational, quasiexperimental design.

2.

The study was delimited to the years 2009-July 2013 when pneumococcal
vaccination data for Kinshasa were collected and made publically
available.

3.

The study was delimited to the data abstracted from the sentinel
surveillance data on pneumococcal illness.

4.

The study was delimited to data collected and provided by the ministry of
health of the Democratic Republic of Congo.

Any provision, condition, variable, or subject not specified was considered beyond the
scope of this study.
Limitations
The following limitations were recognized in this study:
1.

Not all cities/provinces in the DRC reported the percentage of
pneumococcal vaccinated children.

2.

This study used archival data provided by the ministry of health of the
DRC from 2009 to July 2013 for pneumococcal disease.

3.

This is a quasi-experimental study that provided information in a limited
time frame and may not have predicted future vaccination rates.

4.

A weighted average of pneumococcal vaccination rates for children was
used to estimate the percentage of children where there was more than one
service area providing information for a city/province.
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5.

Variations in pneumococcal vaccine effectiveness within different disease
seasons, if appropriate, were taken into account.

6.

Data on the vaccination status and number of doses received were not
collected; therefore, the epidemiology principle of “dose-response” could
not be assessed.
Significance

This study was significant because it had the potential to demonstrate the
effectiveness of controlling a vaccine preventable disease in a part of the world where the
disease is still problematic with a highly effective vaccine for children 5 years of age or
under. The vaccine has the potential to eliminate many sick children and unnecessary
deaths due to pneumococcal infections, thus creating positive social change. This
research study might play a part in the decision-making process relative to pneumococcal
disease burden in the DRC and may assist with the decision to replicate the program in
other provinces in the DRC and/or other African countries (Levine et al., 2006). It might
also help to know the impact of the PCV 13 on the different pneumococcal circulating
serotypes in DRC. The outcome of this study might help improve the quality of the
program because the information obtained can help researchers in developing new
vaccines.
Summary and Transition
Researchers have established vaccination as an essential ingredient for preventing
vaccine preventable diseases. Vaccines induce protection by producing antibodies to fight
against the germs that enter the body, therefore helping reduce morbidity and mortality
(Pittet, & Posfay-Barbe, 2012). Vaccination has been described as one of the 10 greatest
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public health achievements in the 20th century (CDC, 2013). There are many infectious
diseases that are vaccine-preventable, and invasive pneumococcal disease is one of them.
A child who is completely vaccinated acquires immunity against vaccine preventable
diseases (CDC, 2013).
PCV13 protects against the most disease-causing serotypes of streptococcus
pneumoniae. Introducing the vaccine into the routine childhood vaccination schedule
throughout the entire DRC might help reduce the burden of pneumococcal diseases
among the country’s children and promote a healthy population.
In Chapter 2. I present a review of the existing literature and how new research is
suggesting an association between the use of the PCV13 vaccine in the childhood
immunization schedule and the reduction in the incidence of invasive pneumococcal
diseases.
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Chapter 2: Literature Review
Introduction
Invasive pneumococcal diseases are deadly diseases that could be prevented with
available vaccines. The WHO, (2013) estimated that 800,000 children under the age of 5
die each year of invasive pneumococcal disease. Childhood vaccination against this
disease reduces morbidity and mortality (CDC, 2012). According to the immunization
authority, pneumococcal conjugate vaccine (PCV13) was introduced in the DRC in 2011;
however, all provinces have not yet been vaccinated. The vaccine introduction was
completed in only 5 of the 11 provinces of the country. There was the need to know the
impact of the vaccine in order to confidently continue with the introduction in the
remaining provinces.
The purpose of this study was to determine whether there was an association
between the introduction of PCV13 and new cases of pneumococcal disease in two
provinces in central Africa. In the literature review, I establish the need for continued
research concerning the value of the pneumococcal conjugate vaccine that helps the
individual fight off the invading bacteria, thereby protecting him or her from harmful
invasive pneumococcal diseases. The impact of the vaccine on the circulating serotypes
in a geographical area is a relatively new field of research being conducted because the
available vaccines only contain 13 of the 93 serotypes existent. Scholars have examined
the cost effectiveness of the pneumococcal conjugate vaccine, its impact in the reduction
of mortality and morbidity, as well as the importance of prevention through vaccination
as evidenced by the antibiotic’s resistance recently observed.
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The number of doses of vaccine is important for the development of immunity to
the disease. The development of immunity through antibody creation is instrumental in
the recipient’s ability to resist infection, thereby staying healthy and exempting him or
her from deadly vaccine preventable diseases. Vaccination with the three doses of
pneumococcal conjugate vaccine at 2, 4, and 6 months of age is followed up with a
booster dose when the antibody concentration declines (Käyhty, and Eskola, 1996). The
decision to give a booster vaccination is based on the rate of decline and persistence or
not of immunologic memory (Akinsola et al., 2012).
This chapter provides a review of the evolution of the antibody theory,
specifically the inherent importance of the development of immunity after receiving the
appropriate vaccine inoculation. In addition, pneumococcal conjugate vaccine impacts
research relating to the questions addressed in this study. Research on the diseases caused
by the streptococcus pneumonia, the different disease causing serotypes of the bacteria,
the serotypes covered by the available vaccines, and their role in the development of
invasive pneumococcal diseases were incorporated into this chapter. In order to have an
objective discussion of the literature, this chapter includes a discussion of research that
challenges some of the outcomes of research in these areas. The chapter culminates with
an explanation of how past research influenced this study.
Literature Search Strategy
A search of literature was conducted digitally through electronic medical
databases such as Pub Med (NCBI and MeSH databases), Walden library databases
(Academic Search Complete and ScienceDirect), and Google scholar. The list of search
terms used to conduct the literature search included pneumococcal diseases,
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streptococcus pneumonia serotypes, burden of pneumococcal diseases, pneumococcal
conjugate vaccines, and impact of the vaccines on circulating pneumococcal strains. Full
text peer-reviewed articles spanning from 1990 to the last 5 years were obtained digitally
and reviewed for this study.
Theoretical Foundation
The theoretical framework for this study was the epidemic model supported by
the concept of herd immunity. An epidemic model is based on the following assumptions:
(a) infectious disease is transmitted by person-to-person contact only; (b) persons
susceptible to the disease will develop the disease after contact with an infected person,
thereby acquiring immunity to the illness; (c) there is a fixed probability of coming in
contact with an infectious person; (d) the population has no contact with anyone outside
the community; and (e) the conditions remain constant throughout the epidemic (Fine,
1977). Herd immunity or threshold protects susceptible individuals in a community from
disease assuming there is a minimum vaccination threshold (Libster & Edwards, 2011, p.
163; Piedra et al., 2005). Herd immunity applies to infectious disease that can be
transmitted from person to person.
Literature Review
Antibody Theory
According to the antibody theory, health is the multidimensional product of
constant interactions between biological mechanisms, psychological processes, and the
immune system. The antibody theory, as developed by Brein, Haurowitz, Mudd,
Alexander, and Pauling, based on the antigen-template theory assumes that antibodies
can be produced only by cells in which the antigen is present. The specific affinity of an
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antibody molecule toward the antigen is due to a complementarity in structure derived
from the folding of a part of the polypeptide chain of a globulin molecule in direct
contact with a determinant or haptenic region of the antigen. The antigen serves as a
template in the final stage of formation of a globulin molecule. According to the antibody
theory, there is a similarity between antibody formation and adaptive enzyme formation
which allows for the continued production of antibody after the antigen has disappeared
from the body (Jerne, 1955). A renewed contact with the antigen stimulates the
replication of these enzymic units. Circulating antibody molecules are partial replicas of
the modified enzymic units, carrying specificity but lacking enzymatic action (Jerne,
1955).
Vaccines provide protection through immune receptors called antibody in the
presence of a pathogen. The antibodies are produced by the B lymphocytes that can bind
to a pathogen (Siegrist, nd). The T lymphocytes play a role in limiting the spread of the
infection by recognizing and killing infected cells or secreting specific antiviral
cytokines. Most vaccines involve both B and T cells responses (Siegrist, 2008).
In the DRC, the clinical and laboratory diagnostic of pneumococcal diseases are
made based on the WHO’s Algorithm represented in Tables1and 2.
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Table 1
WHO Coordinated Invasive Bacterial Vaccine Preventable Diseases (IB-VPD)
Surveillance Network. Tier 1: Meningitis Surveillance

Case type

Definition

Reference

Suspected
meningitis

Any child aged 0-59 months admitted to a sentinel hospital
conducting surveillance with sudden onset of fever (> 38.5
°C rectal or 38.0 °C axillary) and one of the following signs:
neck stiffness, altered consciousness with no other
alternative diagnosis, or other meningeal sign
Or
Every patient less than 5 years of age hospitalized with a
clinical diagnosis of meningitis.

WHOrecommended
standards for
surveillance of
selected vaccinepreventable
diseases, 2003

Probable
bacterial
meningitis

A suspected meningitis case (as defined above) with CSF
examination showing at least one of the following:
 Turbid appearance;
 Leukocytosis (> 100 cells/mm3);
 Leukocytosis (10-100 cells/ mm3) AND either an
elevated protein (>100 mg/dl) or decreased glucose
(< 40 mg/dl)
Note: if protein and glucose results are not available,
diagnose using the first two conditions (i.e. turbid
appearance or leukocytosis > 100 cells/mm3)

WHOrecommended
standards for
surveillance of
selected vaccinepreventable
diseases, 2003

Confirmed
meningitis

A suspected meningitis case that is laboratory-confirmed by
growing (i.e. culturing) or identifying (i.e. by Gram stain,
antigen detection, immunochromotography, PCR or other
methods) a bacterial pathogen (Hib, pneumococcus or
meningococcus) in the CSF or from the blood in a child with
a clinical syndrome consistent with bacterial meningitis

WHOrecommended
standards for
surveillance of
selected vaccinepreventable
diseases, 2003
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Table 2
WHO Coordinated Invasive Bacterial Vaccine Preventable Diseases (IB-VPD)
Surveillance Network. Tier 2: Meningitis-Pneumonia-Sepsis Surveillance
Case type

Definition

Reference

Pneumonia

Any child aged 0-59 months admitted to a sentinel hospital
conducting surveillance, demonstrating a cough or difficulty
breathing and displaying fast breathing when calm (as
defined by age):
Age 0 to <2 months: 60 breaths/minute or more
Age 2 to < 12 months: 50 breaths/minute or more
Age 12 to <59 months: 40 breaths/minute or more

WHO/UNICEF
Integrated
Management of
Childhood Illness
Chart Booklet Standard, 2008

Severe
pneumonia

Any child aged 0-59 months admitted to a sentinel hospital
conducting surveillance, demonstrating a cough or difficulty
breathing and displaying one or more of the following:
Inability to drink or breastfeed
Vomiting everything
Convulsions
Prostration/lethargy
Chest in-drawing
Stridor when calm

WHO/UNICEF
Integrated
Management of
Childhood Illness
Chart Booklet Standard, 2008

WHO-defined
endpoint
pneumonia

Pneumonia in a patient with a chest radiograph showing an
infiltrate consistent with pneumonia, i.e., dense, fluffy
alveolar consolidation and/or pleural effusion [79].

Cherian T, Mulholland
EK, Carlin JB, et al.
Standardized
interpretation of
pediatric chest
radiographs for the
diagnosis of
pneumonia in
epidemiological
studies. Bull World
Health Organ. 2005
May; 83(5):353-9.

Sepsis

Any child aged 0-59 months admitted to a sentinel hospital
conducting surveillance with the presence of at least 2 of the
following danger signs and without meningitis nor
pneumonia clinical syndrome:
Inability to drink or breastfeed
Vomiting everything
Convulsions (except in malaria endemic areas)
Prostration/lethargy (abnormally sleepy or difficult to wake)
Severe malnutrition
Hypothermia (≤36oC)

EMRO Surveillance for
invasive Hib,
Pneumococcal and
Meningococcal
Diseases. Standard
Operating Procedures
for Clinical and
Laboratory Staff, 2007.

Note. WHO, 2012. Invasive Bacterial Vaccine Preventable Diseases Surveillance Case Definition

24
Pneumococcal Infections
Streptococcus pneumonia, the bacteria responsible for the pneumococcal
infections, colonize the nasopharynx before either infecting the mucosa causing otitis,
pneumonia, or the blood stream causing invasive pneumococcal diseases (Nurhonen,
Cheng, & Auranen, 2013). Pneumococcal diseases cause severe clinical manifestations in
children such as pneumonia, meningitis, sepsis, and bone and joint infections. The
bacterium is responsible for most severe cause of bacterial meningitis in children less
than 5 years of age (Knoll et al., 2009). Infection with the bacteria can lead to extreme
illness and cause loss of life in most cases.
Pneumococcal diseases are classified into two groups: the invasive pneumococcal
diseases (IPDs) and the noninvasive pneumococcal diseases (Ercan, Severge, Topkaya,
Ercan, & Altınkaya, 2011). The case is classified as IPD when the bacteria are isolated
from the blood, cerebro spinal fluid, or pleural fluid and manifesting into meningitis,
sepsis, or bacteremia pneumonia (Adalata, & Riordanb, 2007). The noninvasive disease
is manifested into otitis media, sinusitis, and bronchitis (Ansaldi et al., 2008).
Meningitis
Less common but severe forms of pneumococcal disease are often deadly or leave
the child with a permanent disability. Meningitis or inflammation of the meninges is an
infectious disease affecting the brain membrane and spinal cord that is caused by either
neisseria meningitides or streptococcus pneumonia in most of the cases (Uiterwijk &
Koehler, 2012). The disease is characterized by fever, headache, stiff neck, nausea,
vomiting, photophobia, and altered consciousness. The diagnostic is done by analyzing a
sample of the cerebrospinal fluid after lumbar puncture and detecting the serotype of the
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bacteria (Uiterwijk & Koehler, 2012). Meningitis can be treated with antibiotics
(Uiterwijk & Koehler, 2012).
Pneumonia
The most common severe form of pneumococcal diseases occurs when the
bacteria enters the blood stream and subsequently invades other sites of the body such as
the cerebrospinal fluid (CDC, 2014). Pneumonia is an infection of the lungs caused by
viruses, bacteria, and fungi (CDC, 2014). The most common pneumonia is caused by the
bacteria streptococcus pneumonia (CDC, 2014). Children are most at risk for pneumonia.
The disease is the leading cause of death in children less than 5 years of age worldwide
(CDC, 2014).
Otitis Media
Otitis media is an inflammatory infection of the middle ear caused by
streptococcus pneumonia and is characterized by a collection of fluid (Stephen, 1995). It
is one of the noninvasive forms of pneumococcal diseases (Stephen, 1995).
Serotypes of the Streptococcus pneumonia
Immunochemistry is used with the differentiation of streptococcus pneumonia
into over 93 serotypes grouped into about 48 serogroups. Of those 93-plus serotypes,
only about 15 cause most of the invasive diseases in the world (Onwubiko, Shires, Quin,
Swiatlo, & McDaniel, 2007). Currently the conjugate vaccines available only contain 13
serotypes; there is a need for more vaccine research, but developing a vaccine that will
cover the most frequent serotypes found in invasive diseases is difficult because serotype
distribution is function to age, geographic location, and time (Pai, Gertz, & Beall, 2006).
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Surveillance with the identification of serotypes in countries is important to determine the
vaccine impact after introduction (Hinds et al., nd).
Pneumococcal vaccines
Pneumococcal disease prevention is becoming important as more serotypes are
becoming resistant to antibiotics (Ochoa et al., 2010). Two types of vaccines are currently
available for pneumococcal diseases prevention: the pneumococcal polysaccharide
vaccines and the pneumococcal conjugate vaccines, the latter being the subject of this
study.
Although polysaccharides have been available since the mid-1980s, they are not
recommended for use in children < 2 years probably due to their immature immune
system. In addition, the immune response after vaccination with the polysaccharide is Bcell-dependent with release of IGM as opposed to conjugates vaccines which elicits
mucosal immune response by induction of IgA antibodies (Pletz et al., 2008). Success in
the vaccination of young children came with the development of pneumococcal conjugate
vaccines starting with the seven valents which included the seven most pediatric disease
causing serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F). Compared to polysaccharides
covering 23 serotypes, conjugates vaccines have a low coverage of pneumococcal
serotypes with only 50% protection for infections in adults; although they are effective in
infant against invasive pneumococcal diseases (Pletz et al., 2008).
The pneumococcal polysaccharides vaccine (PPV) contains 23 of the over 90
serotypes of the streptococcus pneumoniae bacteria which were responsible for about
90% of most invasive diseases in the United States and constitute the most antibiotics
resistant strains. There are some drawbacks with the PPV23 even though it is highly
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effective and inexpensive, because of the need to revaccinate in older adults in whom the
effectiveness is only 50 to 70% due to a decline in antibody over time; and its
ineffectiveness in children less than 2 years of age because of the immaturity of their B
cells (Artz, Ershler, & Longo, 2003).
To respond to this problem, alternate vaccines called pneumococcal conjugate
vaccines are being developed by linking the polysaccharide antigens with immunogenic
carrier proteins, activating a response from the T cells and improving the antibody quality
(Chiu, & Mclntyre, 2013). This vaccine not only provides coverage for younger children,
but also longer and durable protection against the strains included in it (Chiu, &
Mclntyre, 2013). The first PCV was licensed in the year 2000 after scholars showed a
decrease in invasive pneumococcal diseases in general and somewhat of otitis media in
children (Chiu, & Mclntyre, 2013). Beside the conjugation of PPV, studies are underway
to develop another vaccine called pneumococcal protein vaccine that will eventually
cover all serotypes of the bacteria with the potential to stimulate immunologic memory
(Artz et al., 2003). Licensing of the PCV vaccines began with the seven valent one
(PCV7) in the year 2000 for the United States and in 2001 or later for Europe and the rest
of the world. This vaccine covered about 80% of the most invasive disease causing
pneumococcal pneumoniae strains in children in the United States and the majority of the
disease causing around the world (Weil-Olivier, van der Linden, de Schutter, Dagan, &
Mantovani, 2012.
The pneumococcal conjugate vaccine is one of the greatest public health
successes in the past decade. In light of the success of the vaccine in drastically reducing
the incidence of invasive disease in infants and children, more research was undertaken to
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include more serotypes leading to the development and licensing of PCV10 and PCV13
respectively from 2008 and 2010 and later in countries. PCV13 recommended use is as
follows (Paradiso, 2011):
1. For all children as a 4-dose series at 2, 4, 6, and 12–15 months of age.
2. Children, 24 months of age who have received >1 dose of PCV7 should complete
the immunization series with PCV13.
3. Children 14–59 months who are fully vaccinated with PCV7 should receive a
single dose of PCV13.
4. Children with underlying medical conditions increasing susceptibility to
pneumococcal infection who are fully vaccinated with PCV7 should receive a
single dose of PCV13.
Impact of Vaccines on the Circulating Strains
PPV was shown to have reduced the disease incidence in adults 65 years or older
and children 2 years and older with certain conditions such as heart disease. According to
the Centers for Disease Control and Prevention (2012), healthy adults who get the PPV
vaccine develop protection within 2 to 3 weeks (Dagan, 2009). PCV has been shown in
studies to be effective against invasive and non-invasive pneumococcal diseases. It was
shown in the literature that PCV reduced the burden of antibiotic resistant streptococcus
pneumoniae serotypes (Dagan, 2009). Particularly vaccination with PVC 7 has been
demonstrated to cause a reduction of the nasopharyngeal carriage types of the penicillin
resistant serotypes of streptococcus (Dagan, 2009).
In a 2009 publication the impact of PCV 7 vaccine on the strains of streptococcus
pneumonia in the United States of America was studied. Data of 1999-2000 and 2004-
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2005 were compared regarding the circulating strains and the antibiotic resistant of them
as well as the impact of the PCV7 on them. The results showed an increased prevalence
of isolates with intermediate penicillin resistance and erythromycin resistance
respectively from 12.7% to 17.9% and from 25.7% to 29.1% and a decreased prevalence
of penicillin resistant isolates from 21.5% to 14.6% between the two respiratory illness
seasons; the prevalence of multidrug resistance did not change. The study also showed
that there was a change in the Streptococcus Pneumoniae population between the two
seasons with an increase of the serotypes 19A (14.5%), 3 (11.2%), 6A (7.1%), 19F (7%)
and 11A (6%) for the period 2004-2005 of whom only 16.3% are included in the PCV 7
vaccine; and a decrease in the prevalence of most of the vaccine containing serotypes.
In conclusion PCV7 has been found to have an impact on the vaccine containing
serotypes (Richter et al, 2009). A study conducted by CDC (2012) in the US have
showed that PCV7 vaccines are highly effective (90%) in younger healthy children
helping disease incidence decrease by 99% for the vaccine serotypes and an increase in
the incidence of invasive pneumococcal diseases due to the serotypes not included in the
vaccine.
Implications of Past Research on Present Research
The impact of pneumococcal vaccines is well documented within the fields of
immunization and vaccine preventable diseases. Vaccination and immunization are
intertwined with disease prevention. The antibody theory has broadened our
understanding of the influence of vaccines on disease prevention (Siegrist, 2008). The
physiological response to an infection and the ability to prevent it depend upon the ability
of the body to produce antibodies in order to react to the infectious agent (Siegrist, 2008).
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In an attempt to better understand the physiological response to infection,
researchers studied the human immune system. Studies began to conclude a direct
connection between the immune system and the protection against diseases in the
presence of infectious agents (Granoff, Gupta, Belshe, & Anderson, 1998). The presence
of an infectious agent stimulates a physiological chain of events that begins with earlyinduced responses to eliminate the infection or hold it in check until specific, acquired
immune responses have time to develop (Granoff, Gupta, Belshe, & Anderson, 1998).
The immune response appears to act like a signaling substance on the nervous system;
engaging the areas of the brain that direct the induction of immunologic memory could be
an important second mechanism of protection (Granoff, Gupta, Belshe, & Anderson,
1998).
The cost effectiveness of vaccination against infections in general and
pneumococcal diseases in particular has been demonstrated in several studies. In a study
conducted in Sweden in 2008 to determine if vaccination with the 7 valents
pneumococcal conjugate vaccine is a cost-effective intervention taking into account herd
immunity has showed that protection of children can be achieved at low and moderate
cost when herd immunity is taken into account. Using a Markov model developed by
Wisloff et al in 2006, the authors have compared a pneumococcal vaccination program
and a no vaccination program of a hypothetical Swedish birth cohort of 95,000 infants
(Bergman et al, 2008).
O’Brien, et al. (2009) in a study attempted to determine if the burden of invasive
pneumococcal diseases was higher in children younger than five years of age compared
to other age groups. The burden was measured using archival data of countries or

31
neighboring countries whenever available, results showed that Pneumococcal disease
caused about 826 000 deaths in children aged 1–59 months around 11% of the overall
mortality in children less than 5 years of age.
Zangeneh, Baracco, & Al-Tawfiq, (2011) provided insight on the approved new
vaccine containing emerging pneumococcal serotypes in addition to the septivalent and
its potential to protect against most disease causing ones. Ayieko et al in their
Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent
Pneumococcal Conjugate vaccination in Kenyan Children found that by investing
annually $14million in the vaccine, 43% of infection with the disease could be avoided;
this could help save $1.97 million in treatment cost and a 6.1 % reduction in child
mortality. Therefore introducing the pneumococcal conjugate vaccine is highly cost
effective (Ayieko et al., 2013).
Literature Relating to Differing Methodologies
The majority of studies in the arena of the impact of the PCV13 have been
correlational in nature due to the difficulty in measuring the vaccine effectiveness. The
relationship between PCV vaccination and prevention against invasive pneumococcal
diseases in children less than 5 years of age has been relatively unexplored, although the
literature suggests a possible connection.
Whitney et al, (2003) provided evidence that the pneumococcal conjugate vaccine
seven valent (PCV7) induced a decline in the invasive disease in children especially the
less than 2 years of age and may also reduce the burden of disease in adults. They have
examined surveillance data from the active bacterial core surveillance of the CDC for the
years 1998-2001 to evaluate the burden of the invasive disease before and after the
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introduction of the PCV-7 vaccine. Sixteen million persons were under surveillance in
2000, of those 433,591 were less than two years of age and 652,551 were between the
ages of two and four. The results showed a drop in the rate of invasive disease after the
introduction of the PCV7 vaccine from an average of 24.3 cases per 100,000 persons in
1998 and 1999 to 17.3 per 100,000 persons in 2001 with the largest decline in the less
than 2 years group.
After comparing the incidence of invasive pneumococcal diseases in children less
than 2 years of age before and after vaccination with PCV7 in a study, the authors
observed a significant decrease of at least 60%. They have concluded that the conjugate
vaccine is effective on children too young to receive the pneumococcal polypeptide. In
this prospective population-based study using laboratory surveillance data, infants aged 0
to 90 days residing in 8 US states were examined for invasive streptococcus pneumoniae
infection during the period of July 1st 1997- June 30 2004. One hundred and forty-six
cases of invasive Pneumococcal Diseases were identified of which 89 before the
introduction of the vaccine and 57 after the introduction (Poehling et al., 2006).
Using a retrospective study of children admitted in a hospital in Alberta, Canada
for complicated pneumonia over a 10 year period (1997-2007); the authors came to the
conclusion that there was an increase in the incidence of complicated pneumonia after
vaccination with PCV 7 with 67% of the cases accounting for the non-vaccine serotypes
prompting the need for new vaccines covering more serotypes. It should be noted that the
data used was 5 years before and 5 years after introduction of the PCV7. Data collected
in the charts of inpatient children up to 17 years of age suffering from complicated
pneumonia (N=228) was examined and have revealed that streptococcus pneumoniae was
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a predominant microorganism identified with non-vaccine serotypes (Chibuk, Robinson,
& Hartfield, 2010).
In a case control study, Ercan, Severge, Topkaya, Ercan, & Altınkaya, (2011)
examined 138 children completely vaccinated with pneumococcal vaccine and 109
unvaccinated control subjects aged 12–59 months. Data from October 2007 and April
2008 was analyzed to determine the effect of the pneumococcal conjugate vaccine on the
pneumococcal carriage in Turkish children. The results did not show a significant
difference in pneumococcal carriage rate between the two groups (10.1% vs 16.5%) but
there was long term protection against the serotypes included in the vaccine.
Another study using a randomized controlled trial analyzed the indirect effect of
7-valent pneumococcal conjugate vaccine on pneumococcal carriage in newborns in rural
Gambia. Twenty villages with infants aged 2-30 months vaccinated with PCV 7 were
compared with ten villages as controls were sampled using nasopharyngeal swabs. The
other villages received meningococcal conjugate vaccine; it was concluded that PCV-7
induced a significant reduction of the vaccine type pneumococcal carriage in the
unvaccinated infant population; the likely reduction probably came from the herd
immunity provided by the children and adults vaccinated population (Egere et al, 2012).
Afonso et al, (2013) used an interrupted time-series to analyze 5 cities in Brazil
that had good data quality and high PCV10 vaccination coverage. They used the data
from the national hospitalization information system from January 2005 to August 2011
to assess the PCV10 effectiveness in children 2-24 months after introduction of the
vaccine in the national immunization program. The results showed that hospitalization of
children for pneumonia was reduced one year after the introduction of the vaccine.
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A study conducted in Uruguay to determine the impact of vaccination with the
pneumococcal conjugate vaccine concluded that the vaccine caused a reduction in the
incidence of pneumonia in hospitalized children in Uruguay five year after the
introduction of the vaccines (PCV7 and PCV13). Also it was concluded that the disease
incidence reduction was higher for PCV13 compared to PCV7. In the study secondary
surveillance data for the years 2009-2012 was used to compare incidence rate pre- PCV
introduction and post-both PCV7 and PCV13 (Hortal, Estevan, Meny, Iraola, & Laurani,
2014).
Summary and Conclusions
The success of smallpox eradication in 1979 by the World Health Organization
and its partners brought the optimism that other childhood vaccines preventable diseases
could be controlled, eliminated or eradicated through vaccination (Gandon & Day, 2007).
According to the literature, the use of vaccines has helped provide protection against a
number of childhood infections (McLean, 1998). The impact of pneumococcal vaccines
was well documented within the fields of immunization and vaccine preventable diseases.
This study added to the existing literature by helping to know the impact of the PCV13
on different kinds of pneumococcal circulating serotypes in DRC.
Chapter 3 describes the methodology used to study the research questions. This
chapter discusses the use of chi-square test of independence and logistic regression as
valid means to analyze the possibility of a relationship between the introduction of the
pneumococcal conjugate vaccine in the childhood immunization schedule and the
reduction of the burden of the invasive pneumococcal diseases. The chapter includes a
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description of the sample population, procedures, ethical considerations, measures, and
analysis of the data.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine whether there was an association
between the introduction of PCV13 and new cases of pneumococcal disease in two
provinces in central Africa. The pneumococcal conjugate vaccine was introduced to five
provinces in the DRC. It was a gradual introduction that will eventually cover the whole
country. No studies have been conducted to date that test the effectiveness of the PCV 13
vaccine in the DRC. This study was the first to attempt to evaluate the impact that this
vaccine has made. The study may also provide insight as to whether or not the vaccine
campaign should be widened to include not only the remaining provinces of the DRC, but
also in the rest of the African countries.
Chapter 3 covers a description of the design, sampling and sample,
instrumentation, data analysis, and ethical considerations. An overview of the study’s
design is given including a rationale for the choice of this particular research design. The
sample characteristics and size, as well as a description of the sampling process, are
presented. The data collection process and analysis are also described in this chapter.
Research Design and Rationale
This study employed a quasi-experimental design using chi-square and logistic
regression analysis. I examined the effect of the vaccination and age and gender at the
intervention site (Kinshasa province) versus the control site (Katanga province) to
determine who got the disease and who did not. The instruments used for measurement of
the variables allowed for the data to be analyzed through chi-square and logistic
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regression. The research questions and the hypotheses reflect this type of analysis. The
hypotheses, corresponding variables and statistical analysis are displayed in table 3.
Table 3
Hypotheses, Corresponding Variables, and Statistical Analysis

Hypothesis
1

2

3

Independent
variable
Province Type:
(Kinshasa,
Katanga)

Dependent
variable
Number of new
cases (Observed,
Not Observed)

Covariate

Province Type:
(Kinshasa,
Katanga)

Number of new
cases (Observed,
Not Observed)

Age

Province Type:
(Kinshasa,
Katanga)

Number of new
cases (Observed,
Not Observed)

Gender

Statistical
Analysis
Chi-square test of
independence

Logistic
Regression
Logistic
Regression

Methodology
In this quantitative secondary data analysis, I explored the relationship between
the reduction in the number of incident cases of invasive pneumococcal disease and the
introduction of PCV13 in the DRC. Disease incidence was compared in a province that
introduced the vaccine, against another province that had not. The impact of the vaccine
on circulating pneumococcal serotypes in the DRC was examined. Individuals considered
for this study included children who lived in the DRC and who had been immunized with
PCV13 starting in April 2011, as recorded in an official regional immunization record in
the Kinshasa province, and a comparison group of the same age in the Katanga province
where the vaccine was not introduced, as well as between sex (male, female). The data
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abstracted were archival data, without personal identifying information as provided by
the immunizing authority.
Population
The research population was obtained from the archival data collected in the three
sentinel surveillance sites in the municipalities of Kalembelembe, Kingasani in Kinshasa,
province of Kinshasa, and the hospital of Sendwe in the town of Lubumbashi, Province
of Katanga from 2009 to July 2013. Each case was pneumococcal positive by one of the
following tests: agglutination test, culture, or PCR. Serotyping is conducted for some of
these cases at the Regional Reference Lab (RRL) of MRC in Gambia. Available archival
data were used for analysis. Permission was received from the government of the DRC
for use of the archival data in the study (Appendix B). Participants selected were (a)
children included in the archival surveillance data of the sentinel surveillance sites, (b)
children of an age where the disease is common, and (c) children presumed to have had
the symptoms of an invasive pneumococcal disease.
Sampling and Sampling Procedures
Archival data from 2009 to July 2013 were extracted from the DRC’s sentinel
surveillance data set. This archived surveillance data set consisted of a representative
sample of children who had visited surveillance sites complaining of signs and symptoms
corresponding with the case definition of pneumococcal disease. The sample did not
include children who had visited other hospitals in the provinces of Kinshasa and
Katanga.
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Power Analysis
Prior to conducting a power analysis, three statistical parameters were set to
ensure appropriateness of sample size. These parameters included power, expected effect
size, and critical alpha. Power was referred to as the probability of finding a statistical
difference between groups provided one existed in the sample data set. For the social
sciences, power is typically set at 80% (Cohen, 1992). This means that there is an 80%
probability that, given the size of the sample collected, a significant difference will be
found. The effect size was the degree of shared variance expected between the variables
of interest. Cohen (1992) defined effect size in terms of Cohen’s was .10 = small, .30 =
medium, and .50 = large.
For this study, a medium expected effect size was adopted (i.e., .30). Critical
alpha is the probability that a significant finding happened by chance. In the social
sciences, critical alpha is usually set at .05 (Cohen, 1992). This means that there is only a
5% chance that the null hypothesis is rejected, when in fact it is true. Accordingly, a
formal power analysis was conducted using the following parameters: (a) power = .80,
(b) effect size = .30, and (c) alpha = .05. Thus, using G*Power 3.0.10 (a sample size
power analysis program), a minimum of 88 participants was needed to produce an 80%
probability of rejecting the null hypothesis (Faul, Erdfelder, Lang, & Buchner, 2007).
Procedure for Data Abstraction
Data were abstracted from the surveillance system; chosen children included in
the DRC’s three sentinels’ sites data for pneumococcal surveillance and treatment
(Kingasani and Kalembelebe in the province of Kinshasa and Sendwe in the province of
Katanga). Children who visited other hospitals than the ones cited above for
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pneumococcal infections in the three hospitals were not included in the study. The
variables of interest to test the hypotheses were age, gender, location, and lab results.
These archival data were originally collected using a case investigation form for
pneumococcal disease designed by the DRC’s ministry of health. The case investigation
form used inquiries about some general information, clinical information, vaccination
status, and outcome at discharge for each participant. The questionnaire also collected
information about the national lab result, the regional lab result, and the antimicrobial
sensibility test result. A copy of the case investigation form is provided in Appendix C. In
some cases, some participants had antibiotic treatment before the collection of cerebro
spinal fluid, possibly influencing the lab result. The data collected during the child’s visit
in one of the sentinel sites was part of the normal surveillance activity as prescribed by
the immunization authority; therefore, no informed consent was necessary.
The questionnaire was scaled at the ordinal scale level. The data were provided
with the identifiers stripped making all results anonymous. All data were extracted from
the surveillance system and recorded using Microsoft Access and Excel. Statistical
Package for the Social Sciences (SPSS) software program was used to analyze the data.
Data analyses were conducted on the entire data set after screening for missing values
and outliers.
Instrumentation
In the DRC, the surveillance system is operated by the ministry of health with the
technical and financial support of the WHO’s country office. The country is subdivided
into health zones comprised of health centers and referral hospitals. Suspect cases are
notified and investigated in health centers and hospitals with sample collection when
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applicable; the sample is then sent to the laboratory for analysis. The data are scrubbed
and entered by the data managers at each level. For this study, the data abstracted were
collected in the three sentinel surveillance sites for the years 2009- July 2013. This is a
credible source of data for pneumococcal disease in the DRC, as the sentinel sites are the
places where most of the suspected pneumococcal disease patients are referred.
All data were obtained from the DRC’s ministry of health. A letter was sent to the
immunization authority requesting data and permission to use available data in this study.
The letter was stamped, approved, and returned (Appendix B). As mentioned above, the
data came from the three sentinel sites were suspect cases for pneumococcal diseases
visit and were hospitalized.
Operationalization of Constructs
Number of instances (observed, not observed). Number of instances (observed,
not observed) is defined as number of cases or occurrences determined by scientific
observation (Ammer, 2013). Number of instances (observed, not observed) was
measured at the nominal level. Part 5 on the case investigation form was used to measure
number of instances (observed, not observed) for invasive pneumococcal disease. Each
question on the case investigation survey was scaled on a nominal scale with results from
different tests specifically culture LCR, Latex, and PCR. 1 = Influenzae, 2 = S.
pneumoniae, 3 = N. meningitidis, 4 = other organism, 5 = Negative. Number of instances
(observed, not observed) was extracted from archival sources, meaning that the data were
gathered at a previous time.
Province type (Kinshasa, Katanga). Province type is defined as a territory
governed as an administrative or political unit of a country or empire (Dictionary.com,
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n.d.). Province type (Kinshasa, Katanga) was measured at the nominal level: 1 =
Kinshasa and 2 = Katanga. Questions included in Part 1, providing the general
information on the case investigation survey questionnaire, were used to measure
province type (Kinshasa, Katanga). Each question on the case investigation questionnaire
was scaled at the nominal level. Province type (Kinshasa, Katanga) was extracted from
archival sources, meaning the data were gathered at a previous time.
Sex. Sex is defined as either of the two main categories (male and female) into
which humans and most other living things are divided on the basis of their reproductive
functions. Sex is used to refer to the biological function (Gentile, 1993). Sex was
measured at the nominal level. Part 1 of the questions on the case investigation form was
used to measure sex: 1 = male, and 2 = female. Sex was extracted from archival sources,
meaning the data were gathered at a previous time.
Table 4
Operationization of Constructs
Variable

Variable Values

Questions

Province type

Kinshasa/ Katanga

Part 1

Number of instances

Observed/not observed

Part 5

Sex

1=Male 2= Female

Part 1

Age group

1= < 2 years 2= 2-5years

Part 1
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Data Analysis Plan
The data were analyzed using the SPSS version 21 to evaluate the impact of the
pneumococcal conjugate vaccine. The aim was to determine whether or not the
introduction of the pneumococcal conjugate vaccine reduced invasive pneumococcal
disease incidence. SPSS 21.0 was used to conduct and tabulate data cleaning and
analyses of the archival data and to provide summary statistics where applicable
including the mean, central tendency, variance, and standard deviation. Logistic
regression analyses were used to evaluate the research questions and to assess whether
the number of incident cases increased or decreased with age and gender, (observed, not
observed) and province type (Kinshasa, Katanga). Archival data were obtained on
number of incident cases of invasive pneumococcal disease by province type to create a 2
x 2 contingency table. Logistic regression was appropriate to analyze the impact of
vaccination on the disease incidence, given the variables (province type and number of
incidence) were scaled at the nominal level.
RQ1: What is the difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV13 and a comparison group in the Katanga province where the
vaccine was not introduced?
Directional Hypothesis 1:
H01: There is no difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV 13 and the Katanga province where the vaccine was not introduced.
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Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a
decrease in the number of incident cases of invasive pneumococcal disease as compared
to the children of the same age in the Katanga province where the vaccine was not
introduced.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: province type: (Kinshasa, Katanga)



Statistical analysis: Chi-square test of independence

RQ2: Is there an association between age and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
Directional Hypothesis 2:
H02: There is no association between age and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha2: Older children (2-5 years) were more likely to contract invasive
pneumococcal disease in the control province compared to the PCV13 intervention
province


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Age



Statistical analysis: Logistic regression
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RQ3: Is there an association between gender and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
Directional Hypothesis 3:
H03: There is no association between gender and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha3: Males were more likely to contract invasive pneumococcal disease in the
control province compared to the PCV13 intervention province.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Gender



Statistical analysis: Logistic regression
Threats to Validity

External Validity
The sample may not have been the best representation of the population, because
it only included patients who visited three hospitals among many; however, it was
assumed to be representative because the three hospitals were chosen for pneumococcal
diseases referral sites, and the most important information was the lab result.
Additionally, the timing of the data collection could affect the way people were thinking
when taking the survey. Finally, the condition of the sick child could have been a
distraction for the parents; people might have wanted the health care worker to quickly
attend to their sick children.
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Internal Validity
Chi-square and logistic regression might not have been the only options to test the
research questions, but they were the best options and the most accurate inferential
statistical tests for this study because I was trying to determine if there was a significant
association between a binomial and a categorical variable. Also, the immunization status
might have been confounding; children might present the disease even though they are
vaccinated, but they might not have had the appropriate number of doses to be
immunized. Also, the quantitative design used in this study to answer the research
questions might not have been exhaustive; this study has benefited from a qualitative
aspect in describing the circulating serotypes of pneumococcal disease in the DRC to see
if they were covered in the PCV 13 vaccine.
Ethical Procedures
The data abstracted for this study were archival surveillance data without personal
identifying information, as provided by the immunizing authority. The data had unique
identification codes. The data were obtained from the ministry of health. Permission was
received from the government of the DRC for use of the archival data in the study
(Appendix B). Walden IRB approval was sought after approval of the proposal and was
obtained, the IRB approval number was 09-04-15-0202213. I reviewed archival data in
electronic copies; therefore, there was no direct contact with the participants. The data
were cleaned before analysis and will be permanently deleted from my computer 5 years
after the study. Any hard copy will be shredded.
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Summary and Transition
I described the methodology in Chapter 3 to help me to understand the
relationship between the vaccination with PCV 13 and the reduction of pneumococcal
disease in the DRC. In this chapter, the use of chi square analysis and logistic regression
as valid means to analyze was discussed, as well as threat to validity, the ethical
concerns, and the procedure for data abstraction. Chapter 4 covers the data abstraction
process, an analysis of the data, and the interpretation of the results.
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Chapter 4: Result
Introduction
The purpose of this study was to determine whether there was an association
between the introduction of PCV13 and new cases of pneumococcal disease in two
provinces in central Africa. I examined the relationship between DRC provinces’
childhood immunization rates for pneumococcal vaccine and the incidence of invasive
pneumococcal disease. The research involved a sample of children who lived in the DRC
and who were immunized with PCV13 starting in April 2011 as recorded in an official
regional immunization record in the Kinshasa province and a comparison group of the
same age in the Katanga province where the vaccine was not introduced. The research
population was obtained from the archival data collected in the three sentinel surveillance
sites in the municipalities of Kalembelembe, Kingasani in Kinshasa, province of
Kinshasa, and the hospital of Sendwe in the town of Lubumbashi, province of Katanga
from 2009 to July 2013. Three research questions were used to guide this quantitative
study. The variables of interest included age, gender, location, and lab results.
This chapter starts with a summary of the applied statistical methods and the
results consisting of a detailed description of the evaluated participants. I then present the
descriptive statistics of the sample and a review of the independent variables in relation to
the dependent variable. The descriptive statistics of the sample are followed by the data
analyses using a chi square test of independence and logistic regression to determine if
the vaccination made a difference in the incidence of pneumococcal disease in the
population moderated by sex, gender, and province type. Finally, this chapter concludes
with a summary of my findings.
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Data Cleaning
Prior to analyzing the research questions, data screening and data cleaning were
undertaken to ensure the variables of interest met appropriate statistical assumptions.
Upon review, it was found that 110 participants of the 490 in the data set were missing
critical information such as age, gender, or lab results. These participants were removed
from the analysis. The total number of participants used in the study was 380.
Description of the Sample
This study’s sample consisted of 380 children who were 5 years of age or under
located in the DRC who have visited surveillance sites complaining of signs and
symptoms that correspond with the case definition of pneumococcal disease during
2009–July 2013. Data were abstracted from a valid sample of 380 participants.
Specifically, there was not much difference between the number of participants who were
males (51.1%, n = 194) and those who were females (48.9%, n =186); additionally,
64.2% of the participants were under 2-years-old (n =244), 35.8% were between 2- and
5-years-old (n = 136), and 21.6% of the participants came from the province of Katanga
(n = 82) and 78.4% came from the province of Kinshasa (n = 298). Described in Table 5
are frequency and percent statistics of participants’ gender, age groups, and province
type.
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Table 5
Frequency and Percent Statistics of Participants’ Gender, Age Groups, and Province
Type
Variables

Frequency

Percent

Gender
Male

194

51.1

Female

186

48.9

< 2 years

244

64.2

2 – 5 years

136

35.8

Katanga

82

21.6

Kinshasa

298

78.4

Age Groups

Province type

Note: total N= 380

Table 6
Frequency of Participants’ Gender, Age Groups by Province Type

Gender

Age group

Note:

total N= 380

Male

Province type
Katanga Kinshasa
45
149

Total
194

Female

37

149

186

< 2 years

67

177

244

2-5 years

15

121

136
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Population and Sample
The population of interest consisted of (a) children included in the archival
surveillance data of the sentinel surveillance sites, (b) children of an age where the
disease is common, and (c) children presumed to have had the symptoms of an invasive
pneumococcal disease. The sample did not include children who had visited other
hospitals in the provinces of Kinshasa and Katanga.
Analysis of Research Questions
The research questions were evaluated using chi-square test of independence and
logistic regression to determine if there is a difference between number of children
diagnosed with the disease (observed, not observed) and province type (Kinshasa,
Katanga ), gender (male, female), and age groups.
The dependent variable for the analyses was the number of incident cases as
measured by the case investigation questionnaire and defined in Chapter 3. The
independent variables were province (Katanga, Kinshasa) type, gender (male, female),
and age groups.
Research Questions and Hypotheses.
The research questions were the following:
RQ1: What is the difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV13 and a comparison group in the Katanga province where the
vaccine was not introduced?
Directional Hypothesis 1:
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H01: There is no difference in the number of incident cases of invasive
pneumococcal disease in children between the Kinshasa province following the
introduction of PCV 13 and the Katanga province where the vaccine was not introduced.
Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a
decrease in the number of incident cases of invasive pneumococcal disease as compared
to the children of the same age in the Katanga province where the vaccine was not
introduced.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: province type: (Kinshasa, Katanga)



Statistical analysis: Chi-square test of independence

RQ2: Is there an association between age and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
Directional Hypothesis 2:
H02: There is no association between age and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha2: Older children (2-5 years) were more likely to contract invasive
pneumococcal disease in the control province compared to the PCV13 intervention
province


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Age
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Statistical analysis: Logistic regression

RQ3: Is there an association between gender and incident cases of invasive
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga
province (control)?
Directional Hypothesis 3:
H03: There is no association between gender and incident cases of invasive
pneumococcal disease in children controlling for province (intervention vs. control)
Ha3: Males were more likely to contract invasive pneumococcal disease in the
control province compared to the PCV13 intervention province.


Dependent variable: Number of incident cases (observed, not observed)



Independent variable: Province type: (Kinshasa, Katanga)



Covariate: Gender



Statistical analysis: Logistic regression

Before conducting the following analyses, the data were assessed using an
analytic strategy in that the variables were first evaluated for missing data, skewness and
Kurtosis, univariate outliers, normality, and linearity. Subsequently, chi-square and
logistic regression analyses were run to determine if any significant difference existed
between the variables of interest.
Chi-square test of independence analysis for research question1
Using SPSS 21, chi-square analysis was conducted to determine if a significant
difference existed in the number of incidence cases of invasive pneumococcal diseases in
children between the Kinshasa province following the introduction of PCV13 vaccine
and a comparison group in the Katanga province where the vaccine was not introduced.
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Because P value = 0.000 < 0.05, I reject the null hypothesis. At α=0.05 level of
significance, there is enough evidence to conclude that a significant difference existed in
the number of incident cases of invasive pneumococcal diseases between the Kinshasa
province following the introduction of PCV 13 vaccine and a comparison group in the
Katanga province where the vaccine was not introduced (χ²= 12.302; p <0.001). The
number of incident cases of invasive pneumococcal disease was significantly higher
among children in the province of Katanga where the PCV 13 vaccine was not
introduced. Summarized details are displayed in Tables 7 and 8.
Table7
2X2 Table Showing Count and Expected Count by Province Type. Final result * Province
type Crosstabulation
Province type
Katanga

Total

Kinshasa

Final

Observed

Count

20

29

49

result

Not Observed

Count

62

269

331

Count

82

298

380

Total
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Table 8
Summary of Chi-Square Analysis for Research Question 1
Value

df

Asymp. Sig. Exact Sig.

Exact Sig.

(2-sided)

(2-sided)

(1-sided)

.001

.001

Pearson Chi-square

12.302a

1

.000

Continuity

11.032

1

.001

10.812

1

.001

Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
Association

12.270

N of Valid Cases

380

1

.000

Note: a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is
10.57.
b. Computed only for a 2x2 table
N= 380
Figure 1 displays the distribution of final results by province type.
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Figure 1: Distribution of final result by province type
Logistic Regression Analyses
Logistic regression analyses were conducted to determine if there were significant
differences in number of incident cases between provinces and between males and
females for the age groups < 2 years and 2-5 years. Specifically, Analysis 2-3 evaluated
differences in incident cases of invasive pneumococcal disease (dependent variable). The
independent variables were gender (male, female), age groups (<2 years old and 2 – 5
years old), and province type (Katanga, Kinshasa). The predictor variable for the two
regression analyses was number of incident cases as defined in Chapter 3. The
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moderating variable for Analysis 2 was age groups (<2-years-old and 2-5-years-old). The
moderating variable for Analysis 3 was gender (male, female).
Logistic Regression Analysis for research question2
Using SPSS 22, binary logistic regression analysis was conducted to determine if
a significant difference existed in the number of incidence cases of invasive
pneumococcal diseases in children aged up to 5 years between the Kinshasa province
following the introduction of PCV13 vaccine and a comparison group of the same age in
the Katanga province where the vaccine was not introduced.
Table 9
Block 0: Beginning Block for Research Question 2. Iteration Historya,b,c
Iteration

Step 0

-2 Log

Coefficients

likelihood

Constant

1

300.730

1.484

2

292.262

1.855

3

292.129

1.909

4

292.129

1.910

5

292.129

1.910

Note: a. Constant is included in the model.
b. Initial -2 Log Likelihood: 292.129
c. Estimation terminated at iteration number 5 because
parameter estimates changed by less than .001.
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Table 10
Variables in the Equation

Step 0

Constant

B

S.E.

Wald

df

1.910

.153

155.755

1

Sig.

Exp(B)

.000

6.755

Table 11
Variables not in the Equation

Step 0

Variables

Score

df

Sig.

Province type(1)

12.302

1

.000

Ag groups(1)

4.356

1

.037

14.383

2

.001

Overall Statistics

Block 0: Beginning Block. Tables 9, 10 and 11 suggests that if I knew nothing about my
variables and guessed that older children (2-5 years) will be more likely to contract
invasive pneumococcal disease in the control province compared to the PCV13
intervention province, I would be correct 87.1% of the time. The variable not in the
equation table means that both variables improve the model, with province type slightly
better than age groups, as both are significant and if included would add to the predictive
power of the model.
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Table 12
Block 1: Method=Enter for research question 2. Iteration Historya,b,c,d
Iteration

Coefficients
-2 Log

Constant

likelihood
Step 1

Province

Agegroups

type(1)

(1)

1

291.915

1.736

-.539

-.211

2

279.464

2.374

-.890

-.429

3

278.925

2.570

-.985

-.543

4

278.923

2.586

-.989

-.555

5

278.923

2.586

-.989

-.555

Note : a. Method: Enter
b. Constant is included in the model.
c. Initial -2 Log Likelihood: 292.129
d. Estimation terminated at iteration number 5 because parameter estimates
changed by less than .001.

Table 13
Omnibus Tests of Model Coefficients
Chi-square
Step 1

df

Sig.

Step

13.207

2

.001

Block

13.207

2

.001

Model

13.207

2

.001
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Block 1 Method = Enter displayed in tables 12 and 13 present the results when the
predictors province type and age groups are included. SPSS prints a classification table
which shows how the classification error rate has not changed from the original 87.1%.
By adding the variables we can still predict with 87.1% accuracy (see classification Table
14 below).
Table 14
Classification Tablea
Observed

Predicted
Final result

Step 1

Final result

Percentage

Observed

Not Observed

Correct

Observed

0

49

.0

Not Observed

0

331

100.0

Overall Percentage

87.1

Note: a. The cut value is .500

Model chi-square is used to test the overall significance. It is the difference between –
2log likelihood for the best-fitting model and –2log likelihood for the null hypothesis
model
There are two hypotheses to test in relation to the overall fit of the model:
H0: The model is a good fitting model.
H1: The model is not a good fitting model.
The –2log likelihood value from the Model Summary table below is 278.923.
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In our case model chi square has 2 degrees of freedom, a value of 13.207 and a
probability of p < 0.01. Thus, the indication is that the model has a poor fit, with the
model containing only the constant indicating that the predictors do have a significant
effect and create essentially a different model.
Table 15
Model Summary
Step

1

-2 Log

Cox & Snell R

Nagelkerke R

likelihood

Square

Square

278.923a

.034

.064

Note: a. Estimation terminated at iteration number 5 because
parameter estimates changed by less than .001.

The Model summary in table 15 provides some approximations of the coefficient of
determination R2.
Here the Cox and Snell’s R-Square is indicating that 3.4% of the variation in the
dependent variable is explained by the logistic model. The Nagelkerke modification that
does range from 0 to 1 is a more reliable measure of the relationship. Nagelkerke’s R2 is
normally higher than the Cox and Snell measure and is the most-reported of the Rsquared estimates. In our case it is 0.064, indicating a weak relationship of 6.4% between
the predictors and the prediction.
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Table 16
Hosmer and Lemeshow Test
Step

Chi-square

df

Sig.

.165

2

.921

1

Table 17
Contingency Table for Hosmer and Lemeshow Test
Final result = Observed

Step 1

Final result = Not Observed

Total

Observed

Expected

Observed

Expected

1

17

17.474

50

49.526

67

2

3

2.526

12

12.474

15

3

21

20.526

156

156.474

177

4

8

8.474

113

112.526

121

Tables 16 and 17 showed that Our H-L statistic has a significance of .921 which means
that it is not statistically significant and therefore our model is quite a good fit. This
desirable outcome of non-significance indicates that the model prediction does not
significantly differ from the observed.
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Table 18
Variables in the Equation

Step
1a

Province
Type (1)
Age
groups (1)
Constant

B

SE

Wald

df

Sig.

Exp
(B)

-.989

.330

9.010

1

.003

.372

95% CI for
EXP (B)
Lower Upper
.195
.709

-.555

.370

2.249

1

.134

.574

.278

2.586

.324

63.699

1

.000

13.280

1.186

Note: a. Variable(s) entered on step 1: Province type, Age groups.

The Wald statistic displayed in table 18 has a chi-square distribution.
In the variable in the equation table, we note that Province type contributed significantly
to the prediction (p = .003) which is less than .05 (we reject the null hypothesis) but Age
groups did not (p = .134), we accept the null hypothesis.
The Exp (B) value associated with Province type is .372 meaning that participants are 0.4
time more likely to belong to the Observed group. The Exp (B) value associated with Age
groups is 0.574; participants are 0.6 time more likely to belong to the observed group.
In this study age group is 0.6 times as important as province type in determining the
decision (see above).
Table 19
Correlation Matrix

Step 1

Constant

Province type(1)

Agegroups(1)

Constant

1,000

-.214

-.796

Province type(1)

-.214

1.000

-.183

Agegroups(1)

-.796

-.183

1.000
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The Correlation Matrix table 19 shows the correlations between each of the predictor
variables and the constant.
Step number: 1
Observed Groups and Predicted Probabilities
200 +
+
I
I
I
N
I
F
I
N
I
R
150 +
N
+
E
I
N
I
Q
I
N
N
I
U
I
N
N
I
E
100 +
N
N
+
N
I
N
N
I
C
I
N
N
I
Y
I
N
N
N
I
50 +
N
N
N
+
I
N
N
N
I
I
N
O
N
I
I
O
N
O
O
I
Predicted ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------Prob:
0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1
Group: OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

Predicted Probability is of Membership for Not Observed
The Cut Value is .50
Symbols: O - Observed
N - Not Observed
Each Symbol Represents 12.5 Cases.

Figure 2. Probability of membership
Figure 2 shows how our full model predicts membership. Accuracy is shown by the
unusually clarity in the middle.
Results Analysis 2
Using SPSS 21.0, Analysis 2 was evaluated using Binary Logistic regression analysis to
determine if a significant relationship existed between the number of incident cases
between the Kinshasa province where PCV 13 was introduced and the Katanga province
where the vaccine was not introduced, and if that relationship was moderated by Age
group. Results indicated that a
test of the full model against a constant only model was statistically significant,
indicating that there is a difference in incident cases of invasive Pneumococcal diseases
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between the Kinshasa province and the Katanga province (chi square = 13.207, p < .01
with df = 2).
Nagelkerke’s R2 of .064 indicated a weak relationship between prediction and grouping.
Prediction success overall was 87.1% (100% for Not observed and 0% for Observed. The
Wald criterion demonstrated that only province type made a significant contribution to
prediction (aOR 0.372, 95% CI 0.709-0.195, P=0.003). Age group was not a significant
predictor (aOR 0.574, 95% CI 1.186-0.278, P= .134)
Logistic Regression Analysis for research question 3
Table 20
Block 0: Beginning Block for analysis 3. Iteration Historya,b,c
Iteration

Coefficients
-2 Log

Constant

likelihood
Step 0

1

300.730

1.484

2

292.262

1.855

3

292.129

1.909

4

292.129

1.910

5

292.129

1.910

Note: a. Constant is included in the model.
b. Initial -2 Log Likelihood: 292.129
c. Estimation terminated at iteration number 5 because
parameter estimates changed by less than .001.
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Table 21
Variables in the Equation
B
Step 0

Constant

1.910

S.E.

Wald

df

Sig.

Exp(B)

.153

155.755

1

.000

6.755

Table 22
Variables not in the Equation
Score
Step 0

Variables

Province type(1)
Gender(1)

Overall Statistics

df

Sig.

12.302

1

.000

.000

1

.996

12.323

2

.002

Block 0: Beginning Block. Tables 20, 21and 22 suggests that if we knew nothing about
our variables and guessed that Males will be more likely to contract invasive
pneumococcal disease in the control province compared to the PCV13 intervention
province we would be correct 87.1% of the time. The variable not in the equation table
tells us that both variables improve the model, with Province type slightly better than Age
groups, as both are significant and if included would add to the predictive power of the
model.
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Table 23
Block 1: Method=Enter for research question 3. Iteration Historya,b,c,d
Iteration

-2 Log
likelihood

Step 1

Coefficients
Constant

Province type(1)

Gender(1)

1

293.228

1.601

-.587

.020

2

281.675

2.090

-.982

.038

3

281.297

2.199

-1.093

.046

4

281.296

2.205

-1.098

.046

5

281.296

2.205

-1.098

.046

Note : a. Method: Enter
b. Constant is included in the model.
c. Initial -2 Log Likelihood: 292.129
d. Estimation terminated at iteration number 5 because parameter estimates
changed by less than .001.

Table 24
Omnibus Tests of Model Coefficients

Step 1

Chi-square

df

Sig.

Step

10.834

2

.004

Block

10.834

2

.004

Model

10.834

2

.004
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Block 1 Method = Enter. Tables 23 and 24 presents the results when the predictors
province type and genders are included. SPSS prints a classification table which shows
how the classification error rate has not changed from the original 87.1%. By adding the
variables we can still predict with 87.1% accuracy (see classification Table 25 below).
Table 25
Classification Tablea
Observed

Predicted
Final result
Observed

Not

Percentage
Correct

Observed
Step 1

Final

Observed

0

49

.0

result

Not

0

331

100.0

Observed
Overall Percentage

87.1

Note: a. The cut value is .500

Model chi-square is used to test the overall significance. It is the difference between –
2log likelihood for the best-fitting model and –2log likelihood for the null hypothesis
model
There are two hypotheses to test in relation to the overall fit of the model:
H0: The model is a good fitting model.
H1: The model is not a good fitting model.
The –2log likelihood value from the Model Summary table below is 281.296.
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In our case model chi square has 2 degrees of freedom, a value of 10.834and a probability
of p= 0.004. Thus, the indication is that the model has a poor fit, with the model
containing only the constant indicating that the predictors do have a significant effect and
create essentially a different model.
Table 26
Model Summary
Step

1

-2 Log

Cox & Snell

Nagelkerke R

likelihood

R Square

Square

281.296a

.028

.052

Note: a. Estimation terminated at iteration number 5 because parameter
estimates changed by less than .001.

The Model summary displayed in Table 26 provides some approximations of the
coefficient of determination R2.
Here the Cox and Snell’s R-Square is indicating that 2.8% of the variation in the
dependent variable is explained by the logistic model. The Nagelkerke modification that
does range from 0 to 1 is a more reliable measure of the relationship. Nagelkerke’s R2 is
normally higher than the Cox and Snell measure and is the most-reported of the Rsquared estimates. In our case it is 0.052, indicating a weak relationship of 5.2% between
the predictors and the prediction.
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Table 27
Hosmer and Lemeshow Test
Step
1

Chi-square

df

Sig.

.016

2

.992

Table 28
Contingency Table for Hosmer and Lemeshow Test
Final result = Observed

Step 1

Final result = Not Observed

Total

Observed

Expected

Observed

Expected

1

9

9.198

28

27.802

37

2

11

10.802

34

34.198

45

3

15

14.802

134

134.198

149

4

14

14.198

135

134.802

149

As displayed in Tables 27 and 28, our H-L statistic has a significance of .992 which
means that it is not statistically significant and therefore our model is quite a good fit.
This desirable outcome of non-significance indicates that the model prediction does not
significantly differ from the observed.
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Table 29
Variables in the Equation

Step
1a

Province
Type (1)
Age
groups (1)
Constant

B

SE

Wald

df

Sig.

Exp
(B)

-1.098

.323

11.533

1

.001

.333

95% CI for
EXP (B)
Lower Upper
.177
.628

.046

.312

.022

1

.882

1.047

.569

2.205

.248

78.905

1

.000

9.066

1.929

Note: a. Variable(s) entered on step 1: Province type, Gender.

The Wald statistic has a chi-square distribution.
In the variable in the equation table, Table 29 we note that province type contributed
significantly to the prediction (p = .001) which is less than .05 (we reject the null
hypothesis) but gender did not (p = .882), we accept the null hypothesis.
The Exp (B) value associated with Province type is .333 meaning that participants are 0.3
time more likely to belong to the Observed group. The Exp (B) value associated with
Gender is 1.047; participants are 1 time more likely to belong to the observed group.
In this study Gender is 0.6 times as important as province type in determining the
decision.
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Table 30
Correlation Matrix

Step 1

Constant

Provincetype(1)

Gender(1)

Constant

1.000

-.445

-.616

Provincetype(1)

-.445

1.000

-.050

Gender(1)

-.616

-.050

1.000

The Correlation Matrix table, Table 30 shows the correlations between each of the
predictor variables and the constant.
Step number: 1
Observed Groups and Predicted Probabilities
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N - Not Observed
Each Symbol Represents 20 Cases.

Figure 3: Membership probability
Figure 3 shows how our full model predicts membership. Accuracy is shown by the
unusually clarity in the middle.
Results Analysis 3
Using SPSS 21.0, Analysis 3 was evaluated using Binary Logistic regression analysis to
determine if a significant relationship existed between the number of incident cases
between the Kinshasa province where PCV 13 was introduced and the Katanga province
where the vaccine was not introduced, and if that relationship was moderated by Gender.
Results indicated that a
test of the full model against a constant only model was statistically significant,
indicating that there is a difference in incident cases of invasive Pneumococcal diseases
between the Kinshasa province and the Katanga province (chi square = 10.834, p = .004
with df = 2).
Nagelkerke’s R2 of 0.052 indicated a weak relationship between prediction and grouping.
Prediction success overall was 87.1% (100% for Not observed and 0% for Observed. The
Wald criterion demonstrated that only province type made a significant contribution to
prediction (aOR 0.333, 95% CI 0.628-0.177, P=0.001). Gender was not a significant
predictor (aOR 1.047, 95% CI 1.929-0.569, P= 0.882).
Descriptive analysis of S. Pneumoniae strains
The circulating Streptococcus Pneumoniae serotypes in the DRC include serotypes
1, 2, 5, 7C, 13, 15B, 19F, 22F, 23A, 23F and 33F. Only four of the 11 serotypes found
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circulating in DRC are included in the PCV 13 vaccine. The results are displayed in table
31.
Table 31
Frequency of Streptococcus Pneumoniae serotypes
Frequency

Valid Percent

Cumulative
Percent

Unknown

31

63.3

63.3

S. Pneum ser 1

4

8.2

67.3

S. Pneum ser 2

2

4.0

71.4

S. Pneum ser 5

1

2.0

73.4

S. Pneum ser 15B

1

2.0

79.6

S. Pneum ser 19F

2

4.1

83.7

S. Pneum ser 23F

2

4.1

87.8

S. Pneum ser 33F

1

2.0

89.8

S. Pneum ser 7C

1

2.0

91.8

S. Pneum ser22F

1

2.0

93.9

S. Pneum ser23A

1

2.0

95.9

S. Pneum ser13

1

2.0

98.0

S. Pneum ser19F

1

2.0

100.0

Total

49

100.0

Table 32 and figure 4 depicts the distribution of the Streptococcus Pneumoniae
serotypes by province type. It should be noted that serotyping was not done for all
positive cases for invasive pneumococcal disease; of the 49 positive cases 31 serotypes
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were unknown. The majority of serotyping was conducted for the Kinshasa province with
only one conducted for the Katanga cases.
Table 32
S. Pneum serotypes by province
Serotypes
Province

S.1 S.2 S.5 S.7C S.13 S.15B S.19F S.22F S.23A S.23F S.33F

Katanga

0

0

1

0

0

0

0

0

0

0

0

Kinshasa

4

2

0

1

1

1

3

1

1

2

1

Total

4

2

1

1

1

1

3

1

1

2

1

Figure4. Serotypes distribution by province
Serotypes distribution was also analyzed by province and by age groups and later
by province and by gender. The results showed that more serotyping was done in the < 2
years age group but that age group also has the most unknown serotypes. As for gender
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the distribution is about the same for both males and females. Results are displayed in
figures 5 and 6. When the analysis was done by crossing age groups and gender, I noted
that males had more serotyping done in the < 2 years of age. Results are depicted in
figure 7.

Figure5. Serotypes distribution by province and by age groups

Figure 6. Serotype distribution by gender
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Figure7. Serotype distribution by gender and by age groups
PCV13 vaccination coverage in Kinshasa province for the years 2011, 2012 and
2013 is displayed in figure 8. The coverage for the first dose of PCV13 is good for 2012
and 2013, it’s below 80 % for 2011, and this can be explained by the fact that 2011 was
the first year of introduction. The third dose is barely at 80% for 2012 but less than 80%
for 2011 and 2013; the country had a shortage of vaccine during 2013.

Figure 8. PCV 13 coverage in Kinshasa province for the years 2011, 2012 and 2013
(January-July 2013)
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Summary and Transition
In summary, pneumococcal vaccination for young children has been shown to
prevent serious illness, hospitalizations, and even death (Rodewald et al, 1999).
According to the World Health Organization, the risk of serious pneumococcal disease
remains high throughout the first 24 months of life (WHO, 2013). My intent for
researching this topic was to examine the relationship between vaccination with PCV13
and the reduction in incidence of invasive pneumococcal diseases, and how this
relationship might be affected by an individual’s gender and age. The Chi-Square and
Logistic Regression analysis conducted in the current study indicated that there was a
significant relationship between vaccination with PCV13 and the reduction in incident
cases for invasive pneumococcal diseases influenced by province type; however the
relationship was not influenced by age group and gender. Table 15 provides a summary
of the results for all analyses. There were no statistically significant relationships between
any of the predictor variables, concluding that the predictor variables and the interaction
effects do not have a significant effect on the outcome variable.
In Chapter 5, I cover a detailed discussion of these results as well as presented the
study limitations, recommendations for future studies, and implications for social change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to determine whether there was an association
between the introduction of PCV13 and new cases of pneumococcal disease in two
provinces in central Africa and how this relationship might be influenced by an
individual’s gender and/or age. The findings of this study contribute to the existing body
of literature (Chibuk, Robinson, & Hartfield, 2010; Ercan, Severge, Topkaya, Ercan, &
Altınkaya, 2011; Poehling et al., 2006; Whitney et al., 2003) on the implications of
vaccination with PCV13 in relation to invasive pneumococcal diseases by confirming or
not the relationship with the reduction of the disease and by determining that most of the
circulating serotypes in the African country are not covered by the PCV13 vaccine. Prior
to the current study, no scholar has explored the association between vaccination with
PCV13 and the reduction in invasive disease in the DRC. This research study filled that
gap by offering a new perspective on the impact of the PCV13 vaccine to the field of
public health. The study’s sample consisted of children 5-years-old or less who live in the
DRC and have visited the sentinel surveillance sites complaining of signs and symptoms
corresponding with the case definition of pneumococcal disease during the years 20092013. The three research questions for this study integrated a chi-square analysis and two
logistic regression analyses to determine the effect of vaccination of PCV13 on the
reduction of invasive pneumococcal diseases and to determine if that effect is dependent
on gender and age. This study was conducted to explore whether there was a relationship
between vaccination with pneumococcal conjugate vaccine and reduction in invasive
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pneumococcal diseases and how this might be affected by a child’s gender or age. The
design of this study was a quantitative, quasi-experimental research design. Data were
derived from DRC’s archival surveillance data for pneumococcal diseases collected from
the established three sentinel surveillance sites.
Interpretation of Findings
In this study, a sample of 380 children located within the DRC was evaluated.
Data were entered into SPSS 21.0 and were then tested using chi-square and logistic
regression analysis to evaluate the research questions.
Results of Research Hypothesis 1
Using SPSS 21.0, Hypothesis 1 was evaluated using a chi-square to determine if
there was a difference between incident cases in Kinshasa province following the
introduction of PCV13 and the Katanga province where the vaccine was not introduced.
Results from Analyses 1 indicated that a significant difference existed in the
number of incident cases of invasive pneumococcal diseases between the Kinshasa
province following the introduction of PCV 13 vaccine and a comparison group in the
Katanga province where the vaccine was not introduced (χ²= 12.302; p <0.001). Because
P value = 0.000 < 0.05, I rejected the null hypothesis. The number of incident cases of
invasive pneumococcal disease is significantly higher among children in the province of
Katanga where the PCV 13 vaccine was not introduced. Because the PCV13 vaccination
coverage was higher than 80% in the Kinshasa province for the years 2012 and 2013, it is
possible that the entire population was protected by heard immunity.
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Results of Research Hypothesis 2
Using SPSS 21.0, Hypothesis 2 was evaluated using logistic regression to
determine if a significant relationship existed between age and incident cases of invasive
pneumococcal disease in children among the Kinshasa province following the
introduction of PCV13 and Katanga province where the vaccine was not introduced.
Results from Analyses 2 indicated that no significant relationship existed between
age and incident cases of invasive pneumococcal disease in children among the Kinshasa
province following the introduction of PCV13 and Katanga province where the vaccine
was not introduced (aOR 0.574, 95% CI 1.186-0.278, P= .134), but that there was a
difference in incident cases of invasive pneumococcal diseases between the Kinshasa
province and the Katanga province (χ²= 13.207, p < .01 with df = 2) confirmed by (aOR
0.372, 95% CI 0.709-0.195, P=0.003).
Results of Research Hypothesis 3
Using SPSS 21.0, Hypothesis 3 was evaluated using logistic regression to
determine if a significant relationship existed between gender and incident cases of
invasive pneumococcal disease in children among the Kinshasa province following the
introduction of PCV13 and Katanga province where the vaccine was not introduced.
Results from Analyses 3 indicated that no significant difference existed between
gender and incident cases of invasive pneumococcal disease in children among the
Kinshasa province following the introduction of PCV13 and Katanga province where the
vaccine was not introduced (aOR 1.047, 95% CI 1.929-0.569, P= 0.882). Because P
value = 0.882 > 0.05, I accepted the null hypothesis. At α=0.05 level of significance there
was enough evidence to conclude that no significant difference existed between males
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and females in the number of incident cases of invasive pneumococcal diseases in
children between the Kinshasa province following the introduction of PCV 13 vaccine
and the Katanga province where the vaccine was not introduced.
These results represent new findings in the DRC that contribute to the literature.
Whitney et al. (2003) provided evidence that the pneumococcal conjugate vaccine seven
valent (PCV7) induced a decline in the invasive disease in children, especially the less
than 2 years of age, and may also reduce the burden of disease in adults. Poehling et al.
(2006) observed a significant decrease of at least 60% in children less than 2 years of age
after vaccination with PCV 7. Researchers have not been able to determine whether the
association between the reduction in invasive disease after vaccination with the
pneumococcal conjugate vaccine and gender exist. This may further lead the DRC’s six
remaining provinces and other African countries to introduce the vaccine. Additionally
the findings have the potential to assist public health practitioners in promoting
prevention of the invasive diseases by adopting childhood vaccination with the PCV13
vaccine. Evidence of the relationship between PCV13 and reduction in the incidence of
invasive pneumococcal diseases was found for children 5 years of age or under, also an
age where the disease is more frequent in DRC. This assisted with distinguishing the age
group at risk of the disease and will help determine actions directed toward these
particular children. The results in this study support prior research findings that had also
affirmed the impact of pneumococcal conjugate vaccines on the reduction of the invasive
diseases mostly in children < 2 years.
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Strengths of the Study
In this study, I identified the age group most at risk for invasive pneumococcal
diseases in the DRC, necessary to better direct interventions. The data obtained from the
DRC government consisted of archival surveillance and vaccination data collected as part
of the national surveillance system. The sample consisted of children 5 years of age and
under who have visited a sentinel surveillance site complaining of symptoms of
pneumococcal disease during the years 2009-2013. The data set files were in Excel and
Access format, which were later imported into SPSS for analysis. For proper analysis, the
data were checked for missing values and tested for normality.
Analytic guidelines were followed to conduct a power analysis in order to
determine the minimum sample size needed. A minimum of 88 participants was required
to produce an 80% probability of rejecting the null hypothesis (Faul et al., 2007). Further,
all data collected are kept private and strictly confidential according to the public health
laws requirements.
Limitations of the Study
The results of this study have a number of limitations that must be acknowledged
as with most research. Despite these limitations to the study findings, the conclusions of
the study make a contribution to the existing body of literature on this subject. First, the
causal relationship between PCV 13 and the reduction in incidence cases of invasive
pneumococcal diseases might not have been accurate in children based on the fact that
only a weighted average of pneumococcal vaccination rates for children was used to
estimate the coverage of children in Kinshasa province. The data provided did not include
vaccination status of the participants with the number of doses. Secondly, serotyping was
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not done for all positive cases, especially in the Katanga province; therefore, all possible
circulating serotypes are unknown to identify if they were included in the PCV13
vaccine. Thirdly, there could be variations in pneumococcal vaccine effectiveness within
different disease seasons; this needs to be taken into account. Finally, this was a quasiexperimental study that provided information in a limited time frame and may not predict
future vaccination rates.
Generalizability
This study targeted only children who have visited one of the three sentinel
surveillance sites, data from other cities were not included. This may have impacted the
generalizability of my results because I only used patients visiting three hospitals among
many; however, it was assumed to be generalizable because the three hospitals were
chosen for pneumococcal diseases referral sites, and the most important information was
the lab result. The sample consisted of children who were up to 5-years-old, residing in
the DRC and had visited the sentinel sites in 2009 – 2013.
Validity
This study was conducted using an archived data that were originally collected
with a case investigation form for pneumococcal disease designed by the DRC’s ministry
of health. The clinical and laboratory diagnostic of pneumococcal diseases were made
based on the WHO’s algorithm provided to member countries (WHO, 2012). Data from
the case investigation form were collected as part of the normal surveillance system for
pneumococcal diseases in DRC. Although the WHO (2012) considered the case
investigation form a reliable and valid tool for diagnosing pneumococcal diseases,
concerns with validity should be considered because I cannot determine whether the
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timing of the data collection could have affected the way people are thinking when taking
the survey. In addition, the condition of the sick child could have been a distraction for
the parents.
Reliability
The pneumococcal diseases case investigation form is a reliable tool that is
dependable and accurate (WHO, 2012). The DRC ministry of health is responsible for
collecting and disseminating data necessary for planning and executing public health
activities in the country. As a reliable source of the nationwide surveillance data for
diseases, the DRC ministry of health facilitates through its specialized offices,
community health planning, and monitoring prevention effectively. To generate reliable
statistics, a minimum sample size of 88 participants was needed according to the power
analysis. As a means to control reliability, 380 DRC national representations of those up
to 5 years were sampled. However, the use of secondary data increases the probability of
measurement error and data variance. Error can occur due to constructs and content
validity of the data collected; however, standard error could have prevented errors to
invalidate the secondary data. For instance, the case investigation questionnaire can have
control over reliability because health care clinicians in the sentinel sites were onsite to
assess clinical findings for pneumococcal diseases. Moreover, participants may have been
improperly classified as not having pneumococcal diseases impacting this present study’s
reliability. Also as a researcher, my actions and attitude when collecting the data could
have caused some measurement errors. Finally, quality control processes such as
checking for missing and normality testing were done before statistical analysis to verify
collection of correct data and ensure the data produces stable and consistent results.
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Recommendations
Recommendations for Future Research
The results of this study provided a basis for a number of recommendations. Some
recommendations for further research are grounded in the limitations listed above. To test
this study’s hypotheses, archival data during 2009 – 2013 was chosen from the DRC
archival surveillance data set. The entire data set was used to reflect the entire population
and to answer the research questions after data cleaning. To better the generalizability to
the DRC population as a whole, a future study may consider including children who have
visited other hospitals in the provinces of Kinshasa and Katanga as part of the larger
group, or may examine these populations individually to gain insights into how they may
be similar to or different from the participant who were eligible for inclusion in the study.
Additional recommendations for further research emerged from an examination of
the results of this study in relation to the literature reviewed in Chapter Two. More
research is needed to find more vaccines covering more serotypes. Further, data analysis
involving circulating serotypes in DRC could add to the knowledge of serotypes not
included in the vaccine.
Recommendations for Practice
Evidence showed that children less than five years are more at risk for invasive
pneumococcal diseases, with an increased incidence in the less than 2 years age group
(Knoll et al., 2009). It was also shown that the PCV13 had an impact in that age group
and on the vaccine contained serotypes (CDC, 2012). Yet, despite the cost effectiveness
many countries had not introduced the PCV13 in their childhood vaccination calendar.
Often medical practitioners only treat the patients with antibiotics, very costly and not
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always affordable especially in sub Saharan Africa. Ayieko et al., (2013) in their
Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent
Pneumococcal Conjugate vaccination in Kenyan Children found that by investing
annually $14million in the vaccine, 43% of infection with the disease could be avoided;
this could help save $1.97 million in treatment cost and a 6.1 % reduction in child
mortality; their findings showed that introducing the pneumococcal conjugate vaccine is
highly cost effective. The mortality caused by invasive pneumococcal diseases is high
due in part to reasons cited above but also to antibiotic resistance observed more and
more (Ayieko et al., 2013). Therefore it is recommended that vaccination with
Pneumococcal conjugates vaccines are put in priority in actions for reducing the
morbidity and mortality caused by invasive pneumococcal diseases in countries. In
addition, entire communities in the Kinshasa province could have been protected since
the vaccination coverage assessed from the immunization data provided by the DRC’s
Ministry of health was at a good level to induce heard immunity.
Implications for Positive Social Change
It is expected that the conclusions of this study will translate into significantly
impacting the way invasive pneumococcal disease, which leads to loss of life or poor
quality of live is handled in the DRC. In 2009 the pneumococcal disease incidence was ≥
3000 per 100,000 children less than 5-years of age in DRC; the mortality rate was
between 300 and 500 per 100,000 children less than 5-years of age (Wang, 2009).
Further, the results can be applied to the remaining provinces where the PCV13 vaccine
was not introduced as well as the African countries who have not yet adopted the
preventive measure. Recommending a broad utilization of PCV 13 vaccination as a

88
measure of preventing a deadly disease will contribute to improving the health of
children in DRC in particular and of the entire world in general. This study focused on
exploring whether there was a relationship between vaccination with PCV13 and the
reduction of invasive pneumococcal diseases, and how this relationship was affected by
an individual’s gender and age. Understanding the connection between PCV13
vaccination and the reduction of the disease provided a basis on which to foster positive
social change in DRC and Africa in general.
Also, the results of this study supported positive social change by broadening the
understanding of a relationship between PCV13 and the reduction in incidence of
invasive pneumococcal diseases in a place like DRC. This increased knowledge will
positively enhance the general public’s understanding of not only the burden of the
diseases on children up to 5-years of age but also the way to prevent them effectively.
Surveillance data in DRC showed circulation of non-vaccine serotypes 2, 7C, 13, 15B,
22F, 23A and 33F. The presence of circulating non vaccine serotypes in DRC suggested
that there is a need for further research for a vaccine including more serotypes likely to
continue decreasing the burden of invasive disease in children.
Conclusion
The consequences of invasive pneumococcal diseases are significant and evidenced
by their yearly high mortality. This constitutes a public health problem that needs to be
addressed. Pneumococcal disease can lead to severe health problems, including
pneumonia, blood infections, and meningitis that can impair an individual’s quality of life
and cause death. Further, existing research indicates that there is a high incidence of
pneumococcal diseases among children worldwide (CDC, 2011). Additionally,
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antibiotics resistance has prompted the recommendation to place attention on prevention
of the diseases; and the most cost effective prevention of pneumococcal disease in
children is through vaccination with pneumococcal conjugate vaccine (Bergman et al.,
2008). The most serotypes containing vaccine available to date is the pneumococcal
conjugate vaccine thirteen valent (PCV13) containing 13 of the most disease causing
streptococcus pneumoniae serotypes. By adopting the vaccine in the child’s vaccination
calendar, public health policy makers and healthcare practitioners can enable positive
outcomes and enhance children quality of life in a cost-effective manner.
The results of this study provided strong evidence for decision-making that will
change the lives of children residing in the DRC, who are up to 5-years of age by
implementing practices that acknowledge and address the burden of pneumococcal
diseases. This study reported ample statistical evidence to suggest an important role for
PCV13 in the reduction of incidence of above cited diseases. However gender and age
were found to have no significant impact on the relationship between PCV13 and the
reduction of the disease incidence. A child that is completely vaccinated acquires
immunity against vaccine preventable diseases (CDC, 2013); According to Esposito and
Principi (2015), vaccination with PCV 13 can protect an entire community through heard
immunity. The results of this study could suggest that more people where protected
through heard immunity because the vaccination coverage with PCV13 in the Kinshasa
province was over 80% for the years 2012-2013. Further, this study supported positive
social change by broadening the understanding of a relationship between PCV13 and the
reduction in incidence of invasive pneumococcal diseases in a place like DRC and
provided guidance for public health policies and services.
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Appendix B: Authorization from the Ministry of Health of DRC

Dr Aissata Coulibaly Diaha
World Health Organization
diahaa@who.int
0817006424

To the Director of the EPI program in the Democratic Republic of Congo
Dear Director,

For my PhD in Epidemiology I chose to study the impact of vaccination with PCV 13 on
the reduction of incident cases of diseases due to streptococcus pneumonia. To that effect
I would like to obtain from the Ministry of Health the authorization to use the following
data:
- Available data from the sentinel surveillance sites of Kalembelembe and
Kingasani in the Kinshasa province and of Sendwe in the Katanga province for
the years 2009 through 2013.
- Surveillance and vaccination data for the districts of Kalembelembe and
Kingasani before and after the introduction of the vaccine and for
Lubumbashi/district of Sendwe where the vaccine was not introduced for the
years 2009-2013.
- Serotype data from the regional reference laboratory for the years 2009-2013.
Hoping to get a favorable answer, please accept my best regards.
Aissata Coulibaly
_________________________________________
Aissata C. Diaha, DDS, MPH, PhD candidate

He wrote OK for authorization and put his stamp of approval.
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Appendix C: Case Investigation Form

INFECTIONS BACTERIENNES INVASIVES – FORMULAIRE D’INVESTIGATION DE CAS SUSPECT
Date d’admission ____ /____ /______ No. ID du cas: _____________

Nom du patient:

Numero du dossier, si disponible ________________________ Nom de l’hôpital: ___________________________
PARTIE 1: INFORMATION GENERALE
Sexe:

Masculin

Féminin

Age

M

J

Date de naissance

J

Nom de père/de la mère: __________________________________________________
ZS de Résidence: ___________________________

Province/Région: __________________________

Ville/village:____________________________________ Village/Quartier: __________________________
Adresse : _________________________

Numéro de téléphone mobile:_______________

PARTIE 2: INFORMATION CLINIQUE
Date de début de la maladie: ______/_____/______
Enfant hospitalisé? _____ (oui/non/pas connu)

Date d’admission: ______/_____/______

Diagnostic à l’admission #1_____________________ Diagnostic à l’admission #2 ____________________
Autres infections co-morbides :……………………………………………………………..
Antibiotiques avant l’admission? _____ (oui/non/pas connu)
Le cas a-t-il eu des signes et symptômes suivants? (cochez tous s’appliquant)
Des convulsions

Incapable de s’alimenter

Antécédent de fièvre

Stridor

Altération de la conscience

Respiration rapide

Déshydratation

Toux

Difficulté de respiration

Tirage sous costal

Nuque raide

Fontanelle bombée

Inconnu

Autre: ________________

Cas répondant à la définition de cas suspect de méningite : Oui/ Non
LCR prélevé? ___ (oui/non) Si oui, date et l’heure du prélèvement: _____/_____/_____ (______:_____)
Aspect de LCR au prélèvement:……………………………Pression : goutte à goutte

hyperbare

Autre Information (par exemple, pourquoi le LCR n’a pas été prélevé?): __________________________
______________________________________________________________________________________

M

A

108

PART 3: STATUT VACCINAL
Vaccination de routine?

O

N

I

Vaccination pendant une campagne?

Nbre
Vaccin Hib?

----- ------ ----- ----

Vaccin Hib?

O

N

I

O: Oui

Vaccin Pneumo?

----- ------ ----- ----

Vaccin Pneumo?

O

N

I

N: Non

Vaccin Meningococcique O

N

I

I: Inconnu

Vaccin Meningococcique ----- ------ ----- ---Dates des doses de Routine Hib:

Dose #1___/____/___ Dose #2 ____/___/____ Dose #3 ____/____/____

Dates des doses de Routine Pneumo: Dose #1___/____/___ Dose #2 ____/___/____ Dose #3 ____/____/____
Dates des doses Routine Meningococcal: Dose #1__/___/___ Dose #2 ____/___/____ Dose #3 ___/____/____
Source d’information? Carte de vaccination

Histoire orale

registre

Inconnue

Commentaire :
Date d’admission ____ /____ /______ No. ID du cas: _____________

Nom du patient:

Numero du dossier, si disponible ________________________Nom de l’hôpital: ___________________________
PARTIE 4: RESULTAT A LA SORTIE
Résultat a la sorite:

Guéri

Date de sortie (ou transfert or décès): ____/____/_____

(veuillez cocher ( √ )

Décès

Sorti contre l’avis médical

Transfert
Des séquelles à la sortie?

O

inconnu

N

I

Si oui, veuillez décrire: _________________________________

Classification finale à la sortie?
Pneumonie

Méningite

Septicémie

Autres

Inconnu

Si autres, spécifier : ___________________

PART 5: RESULTATS DU LABORATOIRE
No d’identification de l’échantillon : ________________
Date de réception du LCR au labo: ____/____/____
Apparence du LCR: (cochez un)
1 - Claire

L’heure de réception: (______:_____ )

Echantillon de LCR traité? 1-Oui

2-Non

Si non, raison de non-traitement?____________________________
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2 - Trouble
3 – Xanthos.

Résultat du LCR enregistré? 1-Oui

4 – Purulent

Résultat de Gram: Cocci G+

5 – Autres

2-Non

Cocci G-

Coccobacille G-

Indéterminé

6 – Hémon.

LCR Protéine: ________ (cochez un) ≤100

>100

9 – Inconnu

LCR Glucose: ________ (cochez un) <40

40-100

>100

Autres spécifiez : _______________________
Résultat culture de LCR

Latex traité? 1-Oui

1-H. influenzae

1-Hib

2-S. pneumoniae

2-S. pneumoniae

3-N. meningitidis

3-N. meningitidis

4- Autre organisme

4-N. mening W135

5-Stérile

5-Négatif

6-Culture non faite

6-Autre non spec.

2-Non

PCR fait? 1-Oui

2-Non

1-H. influenzae
2-S. pneumoniae
3-N. meningitidis
4-Négatif

Autre test fait

Autre, spécifiez : ___________________

1-Binax

2-Identification biochimie
Num leucocytes: _______ (cochez un) <10

10-100

>100

Non fait

3-Optochine
4- facteurs X et V
5-Autre
6-Pas d’autre test

Si autre, résultat : ______________

PART 6: LABORATOIRE DE REFERENCE REGIONAL
L’isolé a-t-il été envoyé au LRR? ____(oui/non)

Si oui, date d’envoi: _____/_____/_____

NOTES: __________________________________________________________________________________
INFECTIONS BACTERIENNES INVASIVES – LABORATOIRE DE REFERENCE REGIONAL
Nom du patient:

Date d’admission ____ /____ /______ No. ID du cas: ________

Numero du dossier, si disponible ____________________Nom de l’hôpital: ___________________________
No d’identification de l’échantillon : ________________

LCR
Echantillon envoyé au LNR? 1-Oui

2-Non

LCR stocké 1-Oui

2-Non

110
Comment était conservé?
Date d’envoi du résultat
du LCR au pavillon:

1-(Congélateur -20ºC)
____/____/____

2-(Congélateur -70ºC)

Pathogène isolé du LCR 1- S. pneumoniae

2- N. meningitidis

3-Hib

4- Autre organisme

Si autre, spécifiez : ________________________________
Autre fluide stérile
Autre liquide stérile prélevé (autre que le sang et le LCR) 1-Oui

2-Non

Quel ? __________________

Résultat de la culture d’autre liquide stérile prélevé : _______________________________________________
Isolat
Isolat envoyé au LRR? 1-Oui
Date d’envoie de l’isolat au LRR:

2-Non
_____/_____/_____

Date de réception par le LRR:

_____/_____/_____
Date d’envoi du résultat au labo national: _____/_____/_____ Date de réception: _____/_____/_____
Commentaire du labo national : ___________________________________________________________

RÉSULTATS DU TEST DE SENSIBILITÉ ANTIMICROBIENNE
H. influenzae
Test fait? 1-Oui

Serotype identifié 1-a
2-Non

2-b

3-c

4-d

5-e

6-f

7-non typé

(cochez 1-Sensible 2-Résistant 3-Intermediare)

Oxacilline (1mg)

Chloramphenicol (30mg)

Cefotaxime (30mg)

Pénicilline (10U)

Cotrimoxazole (25mg)

Ciprofloxacine (5mg)

Ampicilline (10U)

Erythromycin (15mg)

Autres : ____________

111
S. pneumoniae Serotype identifié ________
Test fait? 1-Oui

2-Non

(cochez 1-Sensible 2-Résistant 3-Intermediare)

Oxacilline (1mg)

Chloramphenicol (30mg)

Cefotaxime (30mg)

Pénicilline (10U)

Cotrimoxazole (25mg)

Ciprofloxacine (5mg)

Ampicilline (10U)

Erythromycin (15mg)

Autres :______________

N. mengitidis
Test fait? 1-Oui

Serogroup identifié 1-A
2-Non

2-C

3-Y

4-W135

5-autre

(cochez 1-Sensible 2-Résistant 3-Intermediare)

Oxacilline (1mg)

Chloramphenicol (30mg)

Cefotaxime (30mg)

Pénicilline (10U)

Cotrimoxazole (25mg)

Ciprofloxacine (5mg)

Ampicilline (10U)

Erythromycin (15mg)

Autres :

_________

